

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

JOHN HANCOCK LIFE INSURANCE
COMPANY, JOHN HANCOCK VARIABLE
LIFE INSURANCE COMPANY, and
MANULIFE INSURANCE COMPANY (f/k/a
INVESTORS PARTNER INSURANCE
COMPANY),

Plaintiffs,

v.

ABBOTT LABORATORIES,

Defendants.

CIVIL ACTION NO. 05-11150-DPW
Hon. Judge Douglas P. Woodlock

**ABBOTT LABORATORIES' POST-TRIAL LIST OF WITNESSES, DEPOSITIONS
AND EXHIBITS**

Defendant Abbott Laboratories ("Abbott") respectfully submits this Post-Trial List of Witnesses, Depositions, and Exhibits. Pursuant to the Court's instructions on March 14, 2001, Abbott is concurrently submitting copies of: (1) the affidavits and trial testimony of each witness who testified in Abbott's case in chief; (2) the deposition designations of each witness offered as part of Abbott's case in chief; and (3) a set of the Abbott designated exhibits that have been admitted into evidence, as well as the additional exhibits that Abbott is moving into evidence in accordance with the Court's instructions on March 14, 2008. Pursuant to the Court's request, the affidavits, trial transcripts, and deposition designations have been interlineated to indicate the trial exhibit numbers of each exhibit.

A. Witnesses Who Testified At Trial

Abbott is submitting the interlineated affidavits and trial testimony of the following

witnesses:

1. Stanley Bukofzer
2. Michelle Campbell
3. Jeanne Fox
4. Keith Hendricks
5. Jeffrey Leiden
6. John Leonard
7. Carol Meyer
8. Bruce Rodda
9. Ken Stiles
10. Philip Deemer
11. Avram Tucker

B. Witnesses Who Testified in Deposition

Abbott is submitting the interlineated deposition designations of the following witnesses:

1. Stephen Blewitt
2. Deirdre Daeson
3. Wilma Davis
4. Mark Hair
5. Scott Hartz
6. Lynn Klotz
7. Chris Martinez
8. Roger Nastou
9. Perry Nisen
10. Chris Silber

11. William Lee

12. John Mastromarino

Hancock is separately submitting interlineated deposition designations for the following witnesses, which will include Abbott's counter-designations and, for those witnesses who did not testify at trial, affirmative designations:

1. Stanley Bukofzer

2. Michelle Campbell

3. Marilyn Collicott

4. Thomas Woidat

5. Philip Deemer

6. Jeanne Fox

7. Keith Hendricks

8. Jessica Hopfield

9. Bruce Rodda

10. Jeffrey Leiden

11. John Leonard

12. Lise Loberg

13. Jim Looman

14. Thomas Lyons

15. Bruce McCarthy

16. Carol Meyer

17. James Thomas

18. Azmi Nabulsi

C. Trial Exhibits

Attached as Exhibit A is the list of trial exhibits that were admitted into evidence during the trial. Attached as Exhibit B is the list of trial exhibits Abbott is moving into evidence that are not objected to by Hancock. Attached as Exhibit C is the list of trial exhibits Abbott is moving into evidence that are objected to by Hancock. Abbott has assigned these exhibits provisional trial exhibit numbers, identified by brackets [] around the trial exhibit number, to be assigned if the Court overrules Hancock's objections to these exhibits. For the Court's convenience, attached as Exhibit D is a list of all of Abbott's admitted exhibits and the exhibits Abbott is moving into evidence that corresponds with the Trial Exhibit binders that Abbott is concurrently submitting to the Court. Abbott is also submitting a copy of Hancock's key to its objections as Exhibit E.

ABBOTT LABORATORIES

By its attorneys

/s/ Ozge Guzelsu

Ozge Guzelsu

Michael S. D'Orsi
Peter E. Gelhaar (BBO #188310)
Michael S. D'Orsi (BBO #566960)
DONNELLY, CONROY & GELHAAR LLP
1 Beacon St., 33rd Floor
Boston, Massachusetts 02108
(617) 720-2880

and

Jeffrey I. Weinberger (Admitted Pro Hac Vice)
Gregory D. Phillips (Admitted Pro Hac Vice)
Eric J. Lorenzini (Admitted Pro Hac Vice)
Ozge Guzelsu (Admitted Pro Hac Vice)
MUNGER, TOLLES & OLSON LLP
355 South Grand Avenue, 35th Floor
Los Angeles, CA 90071
(213) 683-9100

Dated: March 26, 2008

CERTIFICATE OF SERVICE

I hereby certify that this document(s) filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on March 26, 2008.

Date: March 26, 2008.

_____/s/ Eric J. Lorenzini

EXHIBIT A

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW
Abbott Laboratories' Admitted Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Date Admitted
501		09/07/2001	Operations Highlights 09/07/2001 Board Meeting Presentation	ABBT0577959 - ABBT0577984		03/11/2008 (Bukofzer Affidavit)
512	D_HJ	00/00/0000	File Memo re: Abbott Laboratories Non Recourse	JH001103 - JH001104	Davis_0010	03/14/2008 (Tucker Affidavit)
530		00/00/2000	John Hancock Abbott Compound Summary Cholinergic Channel Modulator (ABT-594) 2000	JHII021620 - JHII021626		03/06/2008
550		06/20/2000	Klotz Email Preliminary Abbott Basket Analysis (Klotz 7)	JH003080 - JH002090	Klotz_0007	03/14/2008 (Tucker Affidavit)
556		07/11/2000	Klotz Email re: Rest of Research Summaries (Klotz 11)	JH003014 - JH003026	Klotz_0011	03/05/2008
559		07/18/2000	Klotz Email re: First Neuropathic Pain Interview (Klotz 12)	JH002999 - JH003001	Klotz_0012	03/05/2008
561		07/23/2000	Klotz Email re: Questions for Abbott (Klotz 13)	JH002984 - JH002988	Klotz_0013	03/05/2008
569		09/21/2000	Purchase Recommendation re: Abbott Labs ("Non-Recourse")	JH001185 - JH001202	Blewitt_0015	03/14/2008 (Tucker Affidavit)
580		11/20/2000	Fox Email re: FDA Telephone Contact Report ABT-773 (Leonard 51)	ABBT0558681 - ABBT0558683	Leonard_0051	03/11/2008 (Fox Affidavit)
582		11/27/2000	FDA Contact Report [ABT-773 End of Phase 2 Meeting] (Fox 5)	ABBT205257 - ABBT205259	Fox_0005	03/11/2008 (Leonard Affidavit)
586		00/00/2001	ASCO 2001 MMPI Update	ABBT0063643 - ABBT0063649		03/11/2008 (Leonard Affidavit)
587		01/00/2001	ABT-773 Project Status Report Monthly Highlights January 2001	ABBT0000302 - ABBT0000308		03/06/2008 (C. Meyer Affidavit)
591		01/25/2001	Dart Memo re: APU Prioritization Meeting	ABBT0012433 - ABBT000012496		03/13/2008 (Hendricks Affidavit)
607		02/12/2001	Presentation re: ABT-773 Update February 12, 2001 (Meyer 10)	ABBT0576828 - ABBT0576871	Meyer_0010	03/11/2008 (Leonard Affidavit)
608		02/22/2001	Sun Email re: 773 Material	ABBT204959 - ABBT205279		03/06/2008 (C. Meyer Affidavit)
608A	P's IR	02/22/2001	Email from Eugene X. Sun to Stan Bukofzer re: 773 Material	ABBT204959 - 5046		03/11/2008
613		03/00/2001	ABT-773 Ketolide Antibiotic Tablet Monthly Status Project Report March 2001	ABBT0000429 - ABBT0000438		03/06/2008 (C. Meyer Affidavit)
614		03/00/2001	ABT-773 Agenda Presentation	ABBT271783 - ABBT271816		03/11/2008 (Bukofzer Affidavit)
616		03/02/2001	Russell Memo re: 2001 Plan Final Reference Package	ABBT0037509 - ABBT0037608		03/11/2008 (Leonard Affidavit)
620		03/09/2001	ABT-594 Presentation re: Abbott Portfolio Review March 7-9, 2001	ABBT0048632 - ABBT00048645		03/11/2008 (Leonard Affidavit)
621		03/09/2001	Agenda for Portfolio Review Meeting March 7-9, 2001	ABBT0092919 - ABBT0092921		03/11/2008 (Leonard Affidavit)
622		03/09/2001	ABT-773 Craft Presentation re: Abbott Portfolio Review March 7-9, 2001	ABBT0013203 - ABBT0013214		03/06/2008 (C. Meyer Affidavit)
625		03/13/2001	Compound Summary for Cholinergic Channel Modulator ABT-594	JHII021612 - JHII021619		03/06/2008

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW
Abbott Laboratories' Admitted Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Date Admitted
627		03/13/2001	Compound Summary for Matrix Metalloproteinase Inhibitor MMPI Program ABT-518	JHII021607 - JHII021611		03/06/2008
631		03/19/2001	ABT-773 Update March 19, 2001 Presentation	ABBT120465.UR - ABBT120513.UR		03/06/2008 (C. Meyer Affidavit)
638		05/00/2001	ABT-773 Ketolide Antibiotic Tablet Monthly Status Project Report May 2001	ABBT0000508 - ABBT0000519		03/11/2008 (Bukofzer Affidavit)
649		06/20/2001	C. Meyer Email re: ABT 773 Taisho/Abbott Meeting June 26 (Bukofzer 14)	ABBT229367 - ABBT229448	Bukofzer_0014	03/11/2008 (Bukofzer Affidavit)
654		07/00/2001	ABT-773 Ketolide Antibiotic Tablet Monthly Status Project Report July 2001	ABBT0000589 - ABBT0000598		03/11/2008 (Bukofzer Affidavit)
670		11/26/2001	Pals Letter re: Research Funding Agreement Dated as of 03/13/01 - 2002 Preliminary Annual Research Plan (Hendricks 9)	JH000787 - JH000802	Hendrick_0009	03/14/2008 (Tucker Affidavit)
673		01/07/2002	Sun Memo re: PEC and ABT-773 Status	ABBT207773 - ABBT207775		03/11/2008 (Bukofzer Affidavit)
676		12/00/2002	January 2002 ABT-773 Presentation for Miles White	ABBT220665 - ABBT220672		03/11/2008 (Bukofzer Affidavit)
691	803	03/19/2004	Investment Review Report re: Research Funding Agreement	JHII012071 - JHII012074		03/05/2008
692		04/12/2004	Blewitt Letter re: Research Funding Agreement Dated 03/13/01 (Hair 1)	JHII011883 - JHII011886	Hair_0001	03/12/2008 (Campbell Affidavit)
698		09/13/2004	Investment Review Report re: Research Funding Agreement	JHII012067 - JHII012070		03/05/2008
712		03/16/2005	Summary of Available Monthly Project Status Reports as of 03/16/05	JHII021644 - JHII021644		03/06/2008
715		03/22/2005	Campbell Email re: Hancock Audit	ABBT0126575 - ABBT0126575		03/12/2008 (Campbell Affidavit)
724A		00/00/0000	StoneTurn Index (Excel spreadsheet) titled John Hancock-Docment Index			03/06/2008
725A		03/00/2001	ABT-594 Neuronal Nicotinic Receptor Agent, March 2001	ST-AUDIT08798 - ST-AUDIT08803		03/06/2008
725B		01/28/2002	Pharmaceutical Products R&D Global Delivery Expense Report	ST-AUDIT10946 - ST-AUDIT10960		03/06/2008
725C	Admitted as 175C but should be 725C	12/05/2000	ABT-773 Portfolio Review, Dec. 5, 2000	ST-AUDIT03137 - ST-AUDIT03243		03/06/2008
732		06/25/2007	Advanced Life Sciences Form 8-K for the period of June 21, 2007			03/11/2008 (Bukofzer Affidavit)
748		02/02/2001	Project Review ABT-089 and ABT-594	ABBT0002314 - ABBT0002469	Leonard_0036; Collicot_0032	03/11/2008 (Leonard Affidavit)
749		12/21/2000	Comilla Memo re: 2001 Plan Assumption Memo - Pass III	ABBT112987.ur - ABBT112992.ur		03/11/2008 (Leonard Affidavit)
750		01/29/2001	Portfolio Analysis January 2001 Review Reference Materials	ABBT0012369 - ABBT0012387		03/04/2008

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW
Abbott Laboratories' Admitted Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Date Admitted
755		05/04/2001	Abbott Oncology - Global Pharmaceutical R & D Strategy Retreat May 2-4, 2001	ABBT0060730 - ABBT0060767		03/11/2008 (Leonard Affidavit)
756		11/09/2001	Interoffice Memorandum re: Monthly Highlights October 2001	ABBT0003478 - ABBT0003481		03/11/2008 (Leonard Affidavit)
759		01/26/2001	Analgesia Venture 2001 Plan Revised 1/26/01	ABBT144630.ur - ABBT144646.ur	Leonard_0021	03/11/2008 (Leonard Affidavit)
760		12/10/2001	Summary of 12/10/2001 PEC Meeting	ABBT209487 - ABBT209488	Leonard_0044	03/11/2008 (Leonard Affidavit)
761		01/07/2002	Interoffice correspondence re: summary on development status of ABT-773	ABBT0559668 - ABBT0559670	Leonard_0049	03/11/2008 (Leonard Affidavit)
762		11/27/2000	Memorandum re: Meeting Minutes	AUDIT 002817 - AUDIT 002829		03/11/2008 (Leonard Affidavit)
768		01/28/2005	D'Amore Letter re: Research Funding Agreement Dated 03/13/01	ABBT0000167 - ABBT0000168		03/12/2008 (Campbell Affidavit)
780		11/29/2000	Fox Email re: Slides for 12/5 Leiden meeting	ABBT0556816 - ABBT0556822	Fox_0004	03/11/2008 Fox Affidavit)
781		11/28/2000	Fox Email re: Executive Summary of ABT-773 End-of-Phase 2 Mtg w/FDA	ABBT0558150	Fox_0006	03/11/2008 (Fox Affidavit)
782		03/07/2001	Abbott Portfolio Review March 7-9, 2001, ABT-518	ABBT0064316 - ABBT0064330		03/11/2008 (Leonard Affidavit)
784		08/21/2001	ABT-594 Pharma Executive Management Committee Review	ABBT0184372 - ABBT0184496	Leiden_0032	03/12/2008 (Leiden Affidavit)
786		01/28/2002	Pharmaceutical Products R&D Global Discovery Project Expense Report	ABBT0578006 - ABBT0578015		03/13/2008 (Stiles Affidavit)
787		12/05/2000	ABT773 Portfolio Review 12/05/2000	ABBT205088 - ABBT205256		03/11/2008 (Leonard Affidavit)
788		07/25/2001	ABT773 Dosing Options 07/25/2001	ABBT119362.ur - ABBT119446.ur		03/06/2008 (C. Meyer Affidavit)
789		10/00/2001	Monthly Status Project Report for ABT773 Ketolide Antibiotic Tablet, October 2001	ABBT0000726 - ABBT0000735		03/06/2008 (C. Meyer Affidavit)
790		03/00/2002	Monthly Status Project Report for ABT773 Ketolide Antibiotic Tablet, March 2002	ABBT0000962 - ABBT0000971		03/06/2008 (C. Meyer Affidavit)
793		05/12/2001	Abstracts from 2001 ASCO Annual Meeting	ABBT0556350 - ABBT0556356		03/11/2008 (Leonard Affidavit)
795		07/31/2001	Clinical Study Report No. R&D/01/171 ABT-594 Protocol M99-114	ABBT0065982 - ABBT0066097		03/12/2008 (Rodda Affidavit)
798		04/20/2004	Wittenberg Email re: Meeting for Hancock Audit with Wittenberg, Stiles, and Potthoff	ABBT0036399 - ABBT0036399; ABBT0008949 - ABBT0008949	Campbell_0003	03/12/2008 (Campbell Affidavit)
799		06/22/2001	Bukofzer Email re: attaching Final Copy of 773 Decision Analysis	ABBT203851 - ABBT203894	Bukofzer_0015	03/11/2008 (Fox Affidavit)
800		03/00/2001	Summary of Success Probabilities by Project and Franchise Portfolio Analysis (March 2001)	ABBT0047890 - ABBT0047892		03/10/2008
801		04/20/2001	Portfolio Analysis of 2001 Abbott Global Pharmaceutical Development Assets	ABBT0013874 - ABBT0013946		03/10/2008

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW
Abbott Laboratories' Admitted Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Date Admitted
803	Marked as 691 on 3/5/08	07/03/2000	Klotz Email re: Update on Cytostatic Area (Klotz 9)	JH003032 - JH003057	Klotz_0009	03/03/2008
818		07/11/2000	Klotz Email attaching research summaries (Blewitt 17)	JH003014 - JH003026	Blewitt_0017	03/03/2008
834	D_BD	09/29/2004	Affidavit of Stephen J. Blewitt (Blewitt 21)		Blewitt_0021	03/03/2008
835	P's HZ	09/29/2004	E-mail from Gregory Bosco to Carol S. Meyer re: ABT-773 Dev. Plan	ABBT0557552 - 57		03/06/2008
836	D_A	11/00/2000	Cohen Memo Attaching Diligence and Research Plan Documents	ABBT0006627 - ABBT0006700		03/11/2008 (Leonard Affidavit)
837	D_AL	09/20/2001	C. Meyer Email thread re: Portfolio issues update	ABBT203477 - ABBT203484		03/11/2008 (Leonard Affidavit)
838	D_DB	12/11/2000	Calendar Entry Meeting ABT- 594 Power Calculations with Silber, Morris, Leonard	ABBT0125549		03/11/2008 (Leonard Affidavit)
839	D_DF	10/05/2001	Leonard Email re: New Agenda for Monday's PEC Meeting	ABBT224537 - ABBT224539		03/11/2008 (Leonard Affidavit)
840	D_DG	10/05/2001	Chiozzi Email re: October 8 program	ABBT0111238 - ABBT0111240		03/11/2008 (Leonard Affidavit)
841	D_DH	10/08/2001	Interoffice memorandum re: Monthly Highlights - September 2001	ABBT334009 - ABBT334011		03/11/2008 (Leonard Affidavit)
842	D_DN	04/27/2001	Interoffice Memorandum re: Monthly Highlights April 2001	ABBT143066.ur - ABBT143067.ur		03/11/2008 (Leonard Affidavit)
843	D_DO	08/10/2001	Interoffice Memorandum re: Monthly Highlights July 2001	ABBT0003466 - ABBT0003467		03/11/2008 (Leonard Affidavit)
844	D_DQ	01/09/2002	Calendar Entry Meeting ABT- 773 Presentation	ABBT0569033		03/11/2008 (Leonard Affidavit)
845	D_DR	02/08/2002	Interoffice Memorandum re: Monthly Highlights January 2002	ABBT247733 - ABBT247737		03/11/2008 (Leonard Affidavit)
846	D_DS	04/09/2002	Interoffice Memorandum re: Monthly Highlights March 2002	ABBT103547.ur - ABBT103551.ur		03/11/2008 (Leonard Affidavit)
847	D_DT	01/18/2001	Nisen Email re: Goodwin Philanthropy	ABBT0064814 - ABBT064817		03/11/2008 (Leonard Affidavit)
848	D_FC	01/20/2003	Pharmaceutical Products R&D Global Discovery Project Expense Report	ABBT0578016 - ABBT0578022		03/11/2008 (Leonard Affidavit)
849	D_FI	05/12/2001	ASCO Poster re: Phase 2 Study of the Matrix Metalloprotease Inhibitor Prinomastat in Patients with Progressive Breast Cancer	ABBT0556331 - ABBT0556331		03/11/2008 (Leonard Affidavit)
850	D_FK	05/12/2001	Abstracts from Proceedings of ASCO Volume 20, 2001	ABBT0556332 - ABBT0556333		03/11/2008 (Leonard Affidavit)
852	D_Y	03/13/2001	Research Funding Agreement between Abbott Laboratories and John Hancock Life Insurance	JH008074 - JH008211		03/11/2008 (Leonard Affidavit)
853	D_AC	04/27/2001	Fox Email re: FYI Ketek	ABBT110591.ur - ABBT110591.ur		03/11/2008 (Bukofzer Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW
Abbott Laboratories' Admitted Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Date Admitted
854	D_BS	06/11/2007	Crain's Chicago Business Article titled, "Waiting to Exhale. Day of Reckoning nears as biotech firm Advanced Life awaits trial results on new treatment for pneumonia" by Mike Colias			03/11/2008 (Bukofzer Affidavit)
855	D_BU	06/29/2007	Crain's Chicago Business Article titled, "Waiting to Exhale. Clinical Trials" by Mike Colias			03/11/2008 (Bukofzer Affidavit)
856	D_BX	08/21/2007	Life Science Weekly Article titled, "Reports from Advanced Life Sciences Holdings describe recent developments"			03/11/2008 (Bukofzer Affidavit)
857	D_FT	07/23/2001	ABT-773 Presentation	ABBT103191.ur - ABBT103270.ur		03/11/2008 (Bukofzer Affidavit)
859	D_BW	02/13/2001	U.S. Food and Drug Administration Center for Drug Evaluation and Research Web Page Article titled, "Drug-Induced Liver Toxicity"			03/11/2008 (Fox Affidavit)
860	D_EC	12/00/2001	December 2001 PEC Presentation re ABT-773	ABBT120514.ur - ABBT120558.ur		03/12/2008 (Leiden Affidavit)
861	D_BN	10/13/2006	Expert Report of Dr. Bruce Rodda		Rodda_0003	03/12/2008 (Rodda Affidavit)
862	D_BR	02/26/2007	Expert Report of Dr. Bruce Rodda (Statistical Issues)		Rodda_0002	03/12/2008 (Rodda Affidavit)
863	D_FD	12/00/2002	Comprehensive Project Accounting System DINGII Project Detail 12/00/2002	ABBT0578023 - ABBT0578025		03/13/2008 (Stiles Affidavit)
864	D_FE	06/07/2004	Global Pharmaceutical Research and Development Global Development Project Expense Report Site Global All Sites 12/00/2003	ABBT0578026 - ABBT0578031		03/13/2008 (Stiles Affidavit)
865	D_FF	01/14/2005	Global Pharmaceutical Research and Development Global Development Project Expense Report Site Global All Sites 12/00/2004	ABBT0578032 - ABBT0578035		03/13/2008 (Stiles Affidavit)
866	D_FG	12/00/2005	Global Pharmaceutical Research and Development Global Development Project Expense Report Site Global All Sites - 12/00/2005	ABBT0578036 - ABBT0578038		03/13/2008 (Stiles Affidavit)
867	D_EF	08/22/2001	Deemer Email re: outlicensing opportunities attaching introductory slides	ABBT246353 - ABBT246368		03/13/2008 (Deemer Affidavit)
868	D_EG	09/28/2001	Deemer Email re: Deemer Weekly Update	ABBT246248 - ABBT24652		03/13/2008 (Deemer Affidavit)
869	D_EH	10/12/2001	Deemer Email re: Licensing opportunities	ABBT246369		03/13/2008 (Deemer Affidavit)
870	D_EI	10/26/2001	Rosenthal Email re: ABT-518 and hematological cancer	ABBT0086829		03/13/2008 (Deemer Affidavit)
871	D_EL	04/03/2002	Hoff-Velk Email re: Salmedix ABT-518	ABBT0170011 - ABBT0170014		03/13/2008 (Deemer Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW
Abbott Laboratories' Admitted Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Date Admitted
872	D_EM	04/06/2002	ABT-518 Selective Matrix Metalloproteinase MMP Inhibitor - Abbott/Salmedix Collaboration	ABBT0141755 - ABBT0141772		03/13/2008 (Deemer Affidavit)
873	D_EN	04/16/2002	Hoff-Velk Email re: Salmedix Forwarding Jerry's Note	ABBT0089655		03/13/2008 (Deemer Affidavit)
874	D_EO	05/03/2002	Poulos Email re: April highlights	ABBT0542887 - ABBT0542892		03/13/2008 (Deemer Affidavit)
875	D_EP	08/02/2002	Fitzgerald Email re: ABT-518 Outlicense Status	ABBT0086988		03/13/2008 (Deemer Affidavit)
876	D_EQ	08/13/2002	Nabulsi Email re: John Hopkins Cancer Center and Abbott Oncology Collaboration Meeting	ABBT0169420 - ABBT0169421		03/13/2008 (Deemer Affidavit)
877	D_ER	08/14/2002	Presentation to Johns Hopkins re: ABT-518 Selective Matrix Metalloproteinase MMP Inhibitor	ABBT0141711 - ABBT0141728		03/13/2008 (Deemer Affidavit)
878	D_ES	09/24/2003	Hoff-Velk Email re: ABT-518 and Prospective Licensee	ABBT0091538 - ABBT0091539		03/13/2008 (Deemer Affidavit)
879	D_ET	02/20/2004	Asia Trip Report, Feb. 16-20, 2004, Perry Nisen	ABBT0167630 - ABBT0167638		03/13/2008 (Deemer Affidavit)
880	D_EU	05/25/2004	Davidson Email re: ABT518 Negative Clinical Results with AG3340 and Marimastat	ABBT0089550 - ABBT0089551		03/13/2008 (Deemer Affidavit)
881	P's AF	03/22/2001	Email from Philip M. Deemer to Perry D. Nisen re: Hancock and Alcon	AL000403		03/13/2008 (Deemer Affidavit)
882	D_BI	12/06/2005	Investment Review Report re: Research Funding Agreement	JHII012050 - JHII012055		03/14/2008 (Tucker Affidavit)
883	D_BP	01/19/2007	Expert Report of Avram S. Tucker		Tucker_0002	03/14/2008 (Tucker Affidavit)
884	D_BY	12/03/2007	Supplemental Expert Report of Avram S. Tucker			03/14/2008 (Tucker Affidavit)
885	D_FU	02/08/2002	Turner Email attaching year end reports	ABBT0027417 - ABBT0027432		03/14/2008 (Tucker Affidavit)
886	D_FW	03/05/2003	Mangan Email re: February Early Warning Projection	JH002419 - JH002420		03/14/2008 (Tucker Affidavit)
887	D_FX	02/27/2006	Hancock Loan Review Report	JHII021946 - JHII021948		03/14/2008 (Tucker Affidavit)
888	D_FY	08/00/2004	Moody Rating Symbols & Definitions			03/14/2008 (Tucker Affidavit)
889	D_GD	10/23/2007	Supplemental Affidavit of Keith Hendricks dated October 23, 2007			03/14/2008 (Tucker Affidavit)
890	D_GO	00/00/0000	ABT-751 Commercial Forecast	ABBT0003252 - ABBT0003254		03/14/2008 (Tucker Affidavit)
891	D-GP	02/17/2008	Schedule 1A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case			03/14/2008 (Tucker Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW
Abbott Laboratories' Admitted Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Date Admitted
892	D_GQ	02/17/2008	Schedule 1B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case			03/14/2008 (Tucker Affidavit)
893	D_GR	02/17/2008	Schedule 2A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case			03/14/2008 (Tucker Affidavit)
894	D_GS	02/17/2008	Schedule 2B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case			03/14/2008 (Tucker Affidavit)
895	D_GT	02/17/2008	Schedule 3A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case			03/14/2008 (Tucker Affidavit)
896	D_GU	02/17/2008	Schedule 3B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case			03/14/2008 (Tucker Affidavit)
897	D_GV	02/17/2008	Schedule 4A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case			03/14/2008 (Tucker Affidavit)
898	D_GW	02/17/2008	Schedule 4B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case			03/14/2008 (Tucker Affidavit)
899	D_GX	02/17/2008	Schedule 5A and 5B Illustration of Change in Currently Expected Royalties - Low Case and Base Case			03/14/2008 (Tucker Affidavit)
900	D_GY	02/17/2008	Schedule 6A Calculation of 1/3 of Unspent Aggregate Carryover Amount and Schedule 6B Abbott's Reported Program Spending by Compound			03/14/2008 (Tucker Affidavit)
901	D_GZ	02/17/2008	Schedule 7A Abbott Reported Spending in 2001, Schedule 7B 2002 Annual Research Plan, Schedule 7C Calculation of Expected/Nominal Ratio and Schedule 7D "Risk Adjusted" 2002 Preliminary Annual Research Plan			03/14/2008 (Tucker Affidavit)

EXHIBIT B

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (No Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.
502	502	00/00/0000	Klotz Memo re: Packet of materials (Klotz 18)	JH000695 - JH000727	Klotz_0018
507	507	00/00/0000	Document Index Report (Martinez 11)	JHII021645 - JHII021646	Martinez_0011
511	511	00/00/0000	Pertinent Information on Interview Candidates (Klotz 26)	JH002180 - JH002201	Klotz_0026
513	513	00/00/0000	Abbott Laboratories BA Asset Portfolio Details	JHII021956 - JHII021958	
514	514	05/13/1997	Purchase Recommendation re: Metabolex Inc. (Blewitt 1)	JHII012335 - JHII012354	Blewitt_0001
515	515	06/05/1998	Report of Purchase re: Alza Corp. (Blewitt 2)	JHII012446 - JHII012446	Blewitt_0002
516	516	06/10/1998	Purchase Recommendation re: Purdue Pharma etal. (Blewitt 3)	JHII012404 - JHII012411	Blewitt_0003
517	517	08/29/1998	Klotz Letter re: Modified Proposal, Consulting Contract and Product Development Tool (Klotz 3)	JH001702 - JH001706	Klotz_0003
518	518	09/09/1998	Klotz Letter re: Modification to the Consulting Agreement (Klotz 4)	JH001694 - JH001698	Klotz_0004
519	519	01/13/1999	Purchase Recommendation re: Celgene Corp. (Blewitt 4)	JHII012240 - JHII012250	Blewitt_0004
522	522	06/04/1999	Purchase Recommendation re: Purdue (Blewitt 6)	JHII012420 - JHII012428	Blewitt_0006
523	523	06/25/1999	Purchase Recommendation re: Elan (Blewitt 7)	JHII012277 - JHII012283	Blewitt_0007
524	524	07/01/1999	Additional Purchase Recommendation re: Celgene Corp. (Blewitt 8)	JHII012251 - JHII012262	Blewitt_0008
525	525	08/20/1999	Report of Purchase re: Lilly Del Mar (Blewitt 9)	JHII012449 - JHII012461	Blewitt_0009
527	527	00/00/2000	Report of Purchase re: Lilly Del Mar (Blewitt 9)		Hartz_0018
543	543	05/26/2000	Cohen Email Forwarding Latest Proposed Terms Sheet	ABBT0008178 - ABBT0008181	
549	549	06/08/2000	Purchase Recommendation re: Pharma Marketing Ltd	JHII012376 - JHII012388	Blewitt_0010
551	551	06/27/2000	Klotz Email re: Materials for your Comments (Klotz 8)	JH003058 - JH003069	Klotz_0008

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (No Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.
560	560	07/21/2000	Klotz Email to Blewitt re: Moellering Interview (Blewitt 39)	JH002993 - JH002997	Blewitt_0039
562	562	07/28/2000	Klotz Email re: Abbott interview write-up	JH002973 - JH002979	Blewitt_0019
567	567	09/18/2000	Lee Email re: Abbott Hancock - Memo re: Research Funding Agreement (Lee 4)	JH003342 - JH003346	Lee_0004
568	568	09/18/2000	GBSA Spreads to On the run Treasuries 9/16 -9/25/2000	JH0021647 - JH0021649	
573	573	09/28/2000	Thomas Email re: ABT-594 M99-114 Slides for David (Thomas 14)	ABBT0051892 - ABBT0051904	Thomas_0014
603	603	02/00/2001	ABT-594 Neuronal Nicotinic Receptor Agent February 2001	ABBT0000412 - ABBT0000417	
611	611	03/00/2001	Summary of Success Probabilities by Project and Franchise Portfolio Analysis March 2001	ABBT287552 - ABBT287557	
612	612	03/00/2001	ABT-518 Matrix Metalloproteinase Inhibitor Monthly Status Project Report March 2001	ABBT0000349 - ABBT0000354	
617	617	03/06/2001	Silber Email re: ABT-594 - Purdue Response	ABBT0119894 - ABBT0119895	
623	623	03/12/2001	D'Amico Email re: M00235 Patient	ABBT0059464 - ABBT0059464	
624	624	03/12/2001	Adams Email re: Latest Version (Lee 18)	JH010033 - JH010142	Lee_0018
629	629	03/14/2001	Rieser Email re: M00235 PK Validation	ABBT0060789 - ABBT0060789	
634	634	04/00/2001	ABT-518 Matrix Metalloproteinase Inhibitor Monthly Status Project Report April 2001	ABBT0000355 - ABBT0000360	
635	635	04/00/2001	ABT-594 Neuronal Nicotinic Receptor Agent Monthly Status Project Report April 2001	ABBT0000491 - ABBT0000496	

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (No Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.
639	639	05/02/2001	ABT-594 Phase 2B Diabetic Neuropathic Pain Results M99114 Study Review 05/02/2001 Presentation	ABBT0001769 - ABBT0001839	
646	646	06/07/2001	MMPI Working Group Minutes 6/7/01 (Leonard 34)	ABBT0026340 - ABBT0026342	
651	651	06/21/2001	Nabulsi Letter re: ABT-518	ABBT0507879 - ABBT0507879	
652	652	06/28/2001	GBSA Spreads to On the run Treasuries	JHII021462 - JHII021462	
653	653	07/00/2001	ABT-594 Neuronal Nicotinic Receptor Agent Monthly Status Project Report July 2001	ABBT0000612 - ABBT0000618	
661	661	08/21/2001	ABT-594 GPEC Review August 21, 2001	ABBT311519 - ABBT311637	Meyer_0023; McCarthy_0054
663	663	09/17/2001	Deemer Email re: ABT-518 [Handling Out Licensing of ABT-518]	ABBT245619 - ABBT245619	
667	667	10/00/2001	Center for Clinical Assessment Project Status Report October 2001	ST-AUDIT13231 - ST-AUDIT13235	
671	671	12/18/2001	Lyons Letter re: Research Funding Agreement Dated as of 03/13/01 2001 Program Status Report and Related Cost Summary - (Blewitt 44)	JH001065 - JH001068	Blewitt_0044
672	672	12/31/2003	Journal Entries and Balance Sheet	JHII021496 - JHII021498	
677	677	00/00/2003	Compound Summary Cholinergic Channel Modulator ABT-594 (Hair 24)	JHII021620 - JHII021626	Hair_0024
679	679	01/16/2003	Johansson Letter re: Research Funding Agreement Dated as of 03/31/01	ABBT0016048 - ABBT0016051	
680	680	01/22/2003	Certificate Pursuant to Bond Investment Committee Guidelines Adopted 03/19/99	JH001105 - JH001105	
682	682	03/14/2003	Welch Email re: FW: Abbott Labs Heads Up (Nastou_0010)	JH002447 - JH002447	Nastou_0010
688	688	12/19/2003	Investment Report re: Research Funding Agreement	JHII012075 - JHII012078	

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (No Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.
693	693	06/23/2004	Desideri Letter re: Research Funding Agreement Dated 03/13/01	ABBT0000114 - ABBT0000114	
701	701	11/05/2004	D'Amore Letter re: Research Funding Agreement Dated 03/14/01	ABBT0000137 - ABBT0000138	
703	703	12/13/2004	License Agreement between Abbott and ALS	ABBT0027991 - ABBT0028015	
704	704	12/13/2004	Investment Review Report re: Research Funding Agreement	JHII012062 - JHII012066	
709	709	03/09/2005	John Hancock Abbott Research Funding Agreement Audit MH Notes 03/09/05	JHII021636 - JHII021636	
710	710	03/11/2005	John Hancock/Abbott Summary of Available Monthly Project Status Reports as of 03/11/05	JHII021637 - JHII021637	
719	719	06/13/2005	Investment Review Report re: Research Funding Agreement	JHII012079 - JHII012083	
722	722	02/06/2006	Hancock's Responses and Objections to Abbott's 1st Set of Interrogatories (Martinez 7)		Martinez_0007
723	723	00/00/0000	Electronic version of Monte Carlo Simulation (Excel spreadsheet) produced by John Hancock		
724	724	00/00/0000	Electronic version of StoneTurn Index (Excel spreadsheet) titled John Hancock-Document Index		
726	726	00/00/2001	McKinsey Project Map - 2001	MCK00533-539	Hopfield_0014
727	727	03/16/2001	Nabulsi and Janus Letter re: M00-235	ABBT0033105	
728	728	03/16/2001	Nabulsi and Janus Letter re: M00-235	ABBT0033117	
729	729	03/16/2001	Nabulsi and Janus Letter re: M00-235	ABBT0033118	
730	730	05/12/2001	ASCO News Release titled, "Nearly 25,000 Cancer Specialists Meet in San Francisco for ASCO Annual Meeting"		

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (No Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.
738	738	09/16/2005	District Court's Memorandum and Order granting Hancock's Motion For Summary Judgment		
740	740	05/10/2006	Hancock's Supplemental Responses To Abbott's Interrogatories Nos. 5(c), 5(d), 6(c), 6(d), and 10		
741	741	06/23/2006	Hancock's Responses and Objections to Abbott's 2nd Set of Interrogatories		
742	742	09/28/2006	First Circuit Court of Appeal's decision affirming the District Court's Order		
743	743	04/30/2007	Hancock's Responses and Objections to Abbott's 3rd Set of Interrogatories		
746	746	07/16/2007	Hancock's Supplemental Responses to Abbott Interrogatory Nos 2, 3, 5(A)(B)(F), 6(A)(B)(F), and 7		
773	773	9/28/2001	ABT518 Selective Matrix Metalloproteinase MMP Inhibitor	ABBT0014648 - ABBT00146657	
774	774	09/00/2001	ABT-518 Matrix Metalloproteinase Inhibitor	ABBT0000381 - ABBT0000388	
776	776	07/02/2001	Kowaluk Email re: Final 07/03/2001 Update	ABBT290799 - ABBT290837	
791	791	00/00/2001	Plan Assumption Memo Pass 3	ABBT112985.ur - ABBT112992.ur; ABBT112995.ur - ABBT112999.ur; ABBT113015.ur - ABBT113018.ur; ABBT113026.ur - ABBT113029.ur	Woidat_0009
794	794	00/00/0000	John Hancock Abbott Laboratories Research and Development Transaction Investment Analysis Report	JH002424 - JH002429	Blewitt_0012
802	802	03/24/1999	Purchase Recommendation for Idun Pharmaceuticals Inc. (Klotz 6)	JHII012355 - JHII012367	Klotz_0006

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (No Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.
804	804	07/11/2000	Klotz Email re: Edit of Neuropathic Pain Summary (Klotz 14)	JH003007 - JH003013	Klotz_0014
807	807	02/00/2001	ABT-773 Descriptive Memorandum February 2001 (Klotz 19)	JH008153 - JH008209	Klotz_0019
809	809	00/00/2000	Pub Med Abstracts re: ABT- 773 (Klotz 21)	JH002212 - JH002226	Klotz_0021
812	812	03/07/2000	Agreement re: Proposed Summary of Terms (Nastou 1)	JH002308 - JH002311	Nastou_0001
815	815	09/21/2000	Bond Investment Committee Meeting Minutes (Nastou 7)	JH005573 - JH005573	Nastou_0007
817	817	09/30/2002	Blewitt Email forwarding the latest model re: Abbott Labs (Blewitt 13)	JH003142 - JH003158	Blewitt_0013
821	821	06/05/2000	ABT-773 Descriptive Memorandum 05/00/2000 (Blewitt 32)	ABBT246466 - ABBT246471	Blewitt_0032
822	822	00/00/0000	List of Questions for Interviewees re: ABT-773 (Blewitt 38)	JH000655 - JH000658	Blewitt_0038
823	823	07/21/2000	Klotz Email Moellering Interview (Blewitt 39)	JH002993 - JH002997	Blewitt_0039
824	824	07/28/2000	Klotz Email re Abbott Interview Writeup (Blewitt 41)	JH002973 - JH002979	Blewitt_0041
830	830	09/23/2002	Kirkpatrick Email re: Status of JH Compounds Divestment Activities (Nisen 37)	ABBT334838 - ABBT334841	Nisen_0037
831	831	05/22/2001	Nisen Email re: ABT-518 Summary of Findings on MMPI (Nisen 38)	ABBT0064226 - ABBT0064226	Nisen_0038
832	832	05/28/2001	Bronson Email re: ABT-518 Slides Whoops (Nisen 39)	ABBT0033486 - ABBT0033494	Nisen_0039
833	833	06/11/2001	Nisen Email re: MMPI Data from Subject X Additional Info (Nisen 40)	ABBT0063625 - ABBT0063626	Nisen_0040

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (No Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.
902	D_FP	05/01/2000	Klotz Letter re: General Biotechnology and Pharmaceutical Investments Consulting (Klotz 1)	JH001691 - JH001693	Klotz_0001
903	D_FX	02/27/2006	Hancock Loan Review Report	JHII021946 - JHII021948	
904	D_FZ	11/25/2007	ALS Press Release identified as Exhibit 99.1 to Advanced Life Sciences Form 8-K for the period of November 15, 2007		
905	D_GI	08/10/2001	Davidson Memo Results from the ABT-518 Clinical Trial, and ASCO 2001 Update (Nisen 31)	ABBT0049970 - ABBT0049977; ABBT0064227-ABBT0064233	Nisen_0031
906	D_GK	10/29/1999	Abbott Laboratories ABT-594 Investigational New Drug IND Annual Report (Collicott 4)	ABBT335520 - ABBT335570	Collicott_0004
907	D_GN	04/23/2001	M99114 Study Review Presentation (Collicott 39)	ABBT0001749 - ABBT0001758	Collicott_0039
908	D_HB	03/23/2007	John Hancock's Objections and Responses to Abbott Laboratories First Set of Interrogatories in Re John Hancock Life Insurance Co et al vs Abbott Laboratories (Davis 2)		Davis_0002
909	D_HM	07/19/2004	Campbell Email re: Hancock Audit (Martinez 3)	ABBT0000265 - ABBT0000266	Martinez_0003
910	D_HN	08/31/2004	Campbell Email re: John Hancock Audit (Martinez 5)	ABBT0000257 - ABBT0000260	Martinez_0005
911	D_HO	10/26/2004	Campbell Email re: Status on Documents Available for Review (Martinez 6)	ABBT0000250 - ABBT0000253	Martinez_0006
912	D_HP	03/15/2005	Campbell Email re: JH Abbott Audit Documentation (Martinez 9)	ABBT0000280 - ABBT0000284	Martinez_0009

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (No Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.
913	D_HQ	03/17/2005	John Hancock Document Index Report (Martinez 10)	JHII021526 - JHII021594	Martinez_0010
914	D_HR	03/11/2005	Summary of Available Monthly Project Status Reports as of 03/11/2005 (Martinez 19)	JHII021637 - JHII021643	Martinez_0019
915	D_HV	00/00/2003	Compound Summary Dopamine Receptor Agonist Program ABT-724 Report (Martinez 23)	JHII021627 - JHII021635	Martinez_0023
916	D_HX	03/22/2005	Hair Email re: JH Abbott Audit Documentation (Hair 4)	ABBT0000273 - ABBT0000276	Hair_0004
917	D_HY	04/05/2005	Davis Email re John Hancock/Abbott audit issues (Hair 2)	ABBT0000215 - ABBT0000220	Hair_0002
918	D_HZ	03/18/2005	Hair Email re: JH Abbott Audit Documentation (Hair 5)	ABBT0000277 - ABBT0000279	Hair_0005
919	D_IC	06/27/2000	Proposed Summary of Terms Agreement (Lee 1)	AL000115 - AL000119	Lee_0002
920	D_ID	08/17/2000	Deemer Email re: Draft Agreement (Lee 3)	AL000138 - AL000175	Lee_0003
921	D_IL	04/19/2000	Email re: More Model	JH003561 - JH003561	Hartz_0011
922	D_IM	03/26/2002	Email re: Abbott Labs	JH002659 - JH002659	Hartz_0026
923	D_IO	03/27/2003	Email memo re: Abbott Laboratories Research and Funding Agreement	JH002407 - JH002409	Hartz_0032
924	D_IP	06/11/2003	Email re: Abbott Research and Development Agreement	JH003113 - JH003115	Hartz_0037
925	D_IQ	06/17/2003	Email and Report re: Abbott Valuation	JH003107 - JH003112	Hartz_0038
926	D_IR	12/19/2003	Email re: John Hancock vs. Abbott Laboratories	JH004479 - JH004480	Hartz_0039
927	D_IS	02/24/2005	Email re: Abbott	JHII011221 - JHII011221	Hartz_0045
928	D_LB	01/18/2005	Martinez Email re: Audit Thursday (Martinez 8)	ABBT0000235 - ABBT000023	Martinez_0008
929	D_LE	05/20/2001	Nisen Email re: MMPI Summary of ASCO Studies (Nabulsi 25)	ABBT0064234 - ABBT0064234	Nabulsi_0025
930	D_LF	05/12/0001	Compilation of ASCO documents (Nabulsi 27)	ABBT0556321 - ABBT0556349	Nabulsi_0027

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (No Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.
931	D_LH	08/10/2001	Davidson Report re: ABT518 (Nabulsi 34)	ABBT0049970 - ABBT0049977	Nabulsi_0034
932	D_LK	03/28/2005	Report of Documents that were Received by Stone Turn but not Identifiable or Previously Included in the Document Index (Hair 13)	JHII021598 - JHII021598	Hair_0013
933	D_LO	03/18/2005	Report of John Hancock Abbott Summary of Available Monthly Highlights (Hair 19)	JHII021638 - JHII021643	Hair_0019
934	D_LV	09/19/2000	Hartz Email re: Abbott Modeling the Expect Returns and Expected Loss Report (Blewitt 14)	JH003551 - JH003555	Blewitt_0014
935	D_LX	04/01/2005	Faxed letter re: Research Funding Agreement dated as of 03/13/2001 (Blewitt 28)	JHII011911 - JHII011915	Blewitt_0028
936	D_LY	01/11/2001	MMPI Working Group Meeting Minutes dated 01/11/2001 (Loberg 3)	ABBT0045264 - ABBT0045269	Loberg_0003
937	D_LZ	05/11/2001	Oncology Status Report as of 05/11/2001 (Loberg 10)	ABBT0045302 - ABBT0045304	Loberg_0010
938	D_MH	04/00/2001	Excerpts from 2001 April Update GPRD	ABBT0011531-ABBT0011532; ABBT0011547-ABBT0011548	
939	D_BH	09/06/2005	Blewitt Memo re: Report Request # 85 (FOLLOW-UP) - Valuation of Sch BA Part 1 Assets Abbott Laboratories (Blewitt 30)	JHII012056 - JHII012061	Blewitt_0030
940	D_BZ	12/12/2003	Complaint in <i>Hancock Life Ins. Co., et al. v. Abbott Laboratories</i> , No. 03-12501 (<i>Hancock I</i>)		
941	D_CP	06/23/2006	Supplemental Complaint		Friedman_0002
942	D_CS	12/29/2006	First Amended Supplemental Complaint		

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (No Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.
943	D_GH	12/20/2002	Letter re: research Funding Agreement Dated as of 03/13/2001 (Blewitt 43)	JH000807 - JH000817	Blewitt_0043
944	D_LI	01/08/2001	Collicott Email re: M99114 Crf Tracking (Collicott 28)	ABBT240624 - ABBT240624	Collicott_0028
945	D_LS	09/21/2000	John Hancock Purchase Recommendation for Abbott Laboratories (Non-Recourse) (Blewitt 30)	JH002373-JH002390	Blewitt_0030
[954]	D_AK	08/16/2001	Kowaluk Email re: ABT-594 DSG Slides for PEMC Review (McCarthy 53)	ABBT289332 - ABBT289344	McCarthy_0053
[955]	D_AM	10/02/2001	Leonard Memo re: 10/08 PEC Meeting Agenda	ABBT201003 - ABBT201007	McCarthy_0057
[957]	D_AS	12/06/2002	Tyree Memo re: November 2002 Highlights	ABBT0518032 - ABBT0518034	
[958]	D_AT	12/20/2002	Johansson Letter re: Research Funding Agreement Dated as of 03/31/01	JH009977 - JH009978	
[979]	D_GG	05/11/2000	Ketek Profile Report (Blewitt 36)	JH000747 - JH000761	Blewitt_0036
994	D_MI	12/22/1998	M98-826 Phase II Osteoarthritis Pain Trial Protocol	ABBT0052076-ABBT0052167	
995	D_MJ	01/05/1999	M98-833 Neuropathic Pain Protocol	ABBT0050285-ABBT0050361	
996	D_MK	01/05/1999	M97-772 Molar Extraction Protocol	ABBT0052774-ABBT0052856	

EXHIBIT C

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-1150-DPW
Abbott Laboratories' To Be Admitted Trial Exhibit List (Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections
[946]	D_C	07/11/2002	Bukofzer Email re: ABT 773 Communication	ABBT203446 - ABBT203450		Hearsay (ABBT203446-48 ONLY)
[947]	D_H	00/00/2000	DePonti, Poluzzi & Montanero Article titled "QT Interval Prolongation by Non Cardiac Drugs Lessons to be Learned from Recent Experience"		Klotz_0030	Hearsay
[948]	D_I	05/09/2000	Collicott Email re: Resume	ABBT242357 - ABBT242361	Collicut_0001	Hearsay / Irrelevant / Authenticity
[949]	D_L	07/00/2000	Research Analysis Report by Wiqar Shaik Titled, "The Changing Face of Antihistamines and Cardiac Adverse Drug Reactions: A Clinical Perspective		Klotz_0028	Hearsay / Irrelevant
[950]	D_M	08/11/2000	MedWatch Summary of Safety Related Drug Labeling Changes Approved by FDA June 2000		Klotz_0029	Hearsay / Irrelevant
[951]	D_Q	11/01/2000	Tormey Email re: Funding Agreement	JH003740 - JH003814		Irrelevant
[952]	D_AD	05/04/2001	Hansen Email re: Marimastat	ABBT0054230 - ABBT0054231		Hearsay
[953]	D_AJ	08/06/2001	Davidson Email to Nisen re: ABT-518 [Marimastat Shows Promise as Treatment for Unresectable Pancreatic Cancer]	ABBT0049990 - ABBT0049990		Hearsay
[956]	D_AP	08/06/2002	Lyons Email re: ABT-773	ABBT333998 - ABBT333998		Hearsay
[959]	D_AV	02/28/2003	Mathers Memo re: February Highlights	ABBT335048 - ABBT335050		Hearsay
[960]	D_AW	11/12/2003	Tyree Letter re: Research Funding Agreement Dated 03/13/01	ABBT0004519 - ABBT0004520		Used in Settlement Discussions and inadmissible under Fed. R. Evid. 408/Hearsay
[961]	D_AX	00/00/2004	Hancock Program Funding Scenarios (Work Paper)	CRA00127 - CRA00139		Hearsay
[962]	D_BE	10/27/2004	Johansson Letter re: Research Funding Agreement Dated as of 03/31/01	JHII011289 - JHII011291		Hearsay
[963]	D_CL	11/07/2005	Abbott's Response to Hancock's First Request for Production of Documents			Hearsay/Irrelevant

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-1150-DPW
Abbott Laboratories' To Be Admitted Trial Exhibit List (Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections
[964]	D_CM	11/28/2005	D'Amore Letter re: Hancock v. Abbott, Case No. 05-11 I50-DPW			Hearsay
[965]	D_CN	12/09/2005	D'Amore Letter re: Hancock v. Abbott, Case No. 05-11 I50-DPW			Hearsay
[966]	D_CR	12/06/2006	Transcript of Hearing before Honorable Douglas P. Woodlock			Hearsay
[967]	D_DD	08/16/2001	Interoffice memorandum re: ABT-594 Review, August 21, 2001, Pharmaceutical Executive Management Committee	ABBT0048631		Hearsay
[968]	D_DK	02/14/2003	Out-license Anti-infective Compounds Board Document February 14, 2003 Draft 8	ABBT0009617 - ABBT0009618		Authenticity / Hearsay
[969]	D_DL	03/27/2001	Kowaluk Email re: therapeutic strategy evaluations attaching briefing document portfolio review	ABBT327314 - ABBT327327		Hearsay (ABBT327316-27)
[970]	D_DP	10/08/2001	Interoffice Memorandum re: Monthly Highlights September 2001	ABBT0003482 - ABBT0003484		Hearsay
[971]	D_DW	03/30/2004	Transcript of March 30, 2004 Hearing in Hancock I			Hearsay
[972]	D_EW	04/09/2001	Kowaluk Email re: Portfolio Probabilities	ABBT285535 - ABBT285536		Hearsay
[973]	D_FM	11/03/2000	Davidson Email re: JCO paper on Bayer compound	ABBT0057776 - ABBT0057777; ABBT0057787 - ABBT0057843		Multiple Documents / Hearsay
[974]	D_FN	03/05/2001	Drug document compound details for Marimastat	ABBT0026863 - ABBT0026866		Hearsay
[975]	D_FQ	02/05/2001	McCarthy Email re: DSG with reply by Kowaluk (McCarthy 38)	ABBT328810 - ABBT328812	McCarthy_0038	Hearsay
[976]	D_FR	10/23/2001	McCarthy Email re: Non Confidential Briefing on ABT-594 (McCarthy 61)	ABBT246791 - ABBT246792	McCarthy_0061	Hearsay

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-1150-DPW

Abbott Laboratories' To Be Admitted Trial Exhibit List (Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections
[977]	D_GE	10/17/2000	Draft Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co Dated as of 10/00/2000 (Blewitt 22)	AL000481 - AL000521	Blewitt_0022	Irrelevant
[978]	D_GF	03/00/2001	Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co Dated as of 03/00/2001 (Blewitt 23)	AL001323 - AL001377	Blewitt_0023	Irrelevant
[980]	D_GJ	04/10/2001	Redenbach - Mueller Email re: Fw Pharma Strategy Retreat Virus Checked (Hopfield 23)	ABBT294218 - ABBT294247	Hopfield_0023	Hearsay (ABBT294218-20)
[981]	D_GM	01/18/2001	Collicott Email re: ABT-594 Completion of Study for Neuropathic Pain (Collicott 30)	ABBT240417 - ABBT240417	Collicott_0030	Hearsay
[982]	D_HA	03/23/2007	Rule 30b6 Notice of Deposition of the Person or Persons Most Knowledgeable to Testify on Behalf of John Hancock Life Insurance Co John Hancock Variable Life Insurance Co and Manulife Insurance Co fka Investors Partners Insurance Co in Re John Hancock Life Insurance Co et al vs Abbott Laboratories (Davis 1)		Davis_0001	Irrelevant
[983]	D_HG	9/21/2000	Hartz Email re: Abbott (Davis 7)	JH002414 - JH002414	Davis_0007	Hearsay
[984]	D_HK	06/15/2004	Desideri Letter re: Research Funding Agreement (Martinez_0001)	ABBT0000077 - ABBT0000078	Martinez_0001	Irrelevant
[985]	D_IE	10/04/2000	Email re: Abbott John Hancock Research Funding Agreement (Lee 6)	JH003270 - JH003341	Lee_0006	Irrelevant/Hearsay

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-1150-DPW
Abbott Laboratories' To Be Admitted Trial Exhibit List (Objections)

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections
[986]	D_IF		Lee Facsimile re: Draft Research Funding Agreement	JH008376 - JH008384	Lee_0017	Irrelevant
[987]	D_LW	03/00/2001	Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co. et al. dated as of 03/00/2001 9 (Blewitt 24)	JH006002 - JH006009	Blewitt_0024	Irrelevant
[988]	D_MB	06/03/2004	Campbell Email re: Hancock Audit (Campbell 10)	ABBT0126520 - ABBT0126520	Campbell_0010	Hearsay
[989]	D_MC	06/04/2004	Wendrick Email re: Hancock Audit (Campbell 11)	ABBT0126590 - ABBT0126592	Campbell_0011	Hearsay
[990]	D_MD	06/10/2004	Pavelske Email re Hancock Audit (Campbell 12)	ABBT0190551 - ABBT0190552	Campbell_0012	Hearsay
[991]	D_ME	06/10/2004	Wendrick Email re: Hancock Audit Monday (Campbell 14)	ABBT0190544 - ABBT0190549	Campbell_0014	Hearsay
[992]	D_MF	08/05/2004	Letter re: Research Funding Agreement between Abbott Laboratories Abbott and John Hancock Life Insurance Co. et al. dated 03/13/2001 (Campbell 21)	ABBT0000125 - ABBT0000127	Campbell_0021	Hearsay
[993]	D_MG	02/19/2008	ALS Press Release entitled "Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin"			Hearsay
[997]	D_ML	03/27/2000	Roth, Fleischmann Article titled "Around-the-Clock, Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain Placebo-Controlled Trial and Long-Term Evaluation"			Hearsay

EXHIBIT D

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
501		09/07/2001	Operations Highlights 09/07/2001 Board Meeting Presentation	ABBT0577959 - ABBT0577984			03/11/2008 (Bukofzer Affidavit)
502	502	00/00/0000	Klotz Memo re: Packet of materials (Klotz 18)	JH000695 - JH000727	Klotz_0018	No Objection	
507	507	00/00/0000	Document Index Report (Martinez 11)	JHII021645 - JHII021646	Martinez_0011	No Objection	
511	511	00/00/0000	Pertinent Information on Interview Candidates (Klotz 26)	JH002180 - JH002201	Klotz_0026	No Objection	
512	D_HJ	00/00/0000	File Memo re: Abbott Laboratories Non Recourse	JH001103 - JH001104	Davis_0010		03/14/2008 (Tucker Affidavit)
513	513	00/00/0000	Abbott Laboratories BA Asset Portfolio Details	JHII021956 - JHII021958		No Objection	
514	514	05/13/1997	Purchase Recommendation re: Metabolex Inc. (Blewitt 1)	JHII012335 - JHII012354	Blewitt_0001	No Objection	
515	515	06/05/1998	Report of Purchase re: Alza Corp. (Blewitt 2)	JHII012446 - JHII012446	Blewitt_0002	No Objection	
516	516	06/10/1998	Purchase Recommendation re: Purdue Pharma etal. (Blewitt 3)	JHII012404 - JHII012411	Blewitt_0003	No Objection	
517	517	08/29/1998	Klotz Letter re: Modified Proposal, Consulting Contract and Product Development Tool (Klotz 3)	JH001702 - JH001706	Klotz_0003	No Objection	
518	518	09/09/1998	Klotz Letter re: Modification to the Consulting Agreement (Klotz 4)	JH001694 - JH001698	Klotz_0004	No Objection	
519	519	01/13/1999	Purchase Recommendation re: Celgene Corp. (Blewitt 4)	JHII012240 - JHII012250	Blewitt_0004	No Objection	
522	522	06/04/1999	Purchase Recommendation re: Purdue (Blewitt 6)	JHII012420 - JHII012428	Blewitt_0006	No Objection	
523	523	06/25/1999	Purchase Recommendation re: Elan (Blewitt 7)	JHII012277 - JHII012283	Blewitt_0007	No Objection	
524	524	07/01/1999	Additional Purchase Recommendation re: Celgene Corp. (Blewitt 8)	JHII012251 - JHII012262	Blewitt_0008	No Objection	
525	525	08/20/1999	Report of Purchase re: Lilly Del Mar (Blewitt 9)	JHII012449 - JHII012461	Blewitt_0009	No Objection	
527	527	00/00/2000	Report of Purchase re: Lilly Del Mar (Blewitt 9)		Hartz_0018	No Objection	
530		00/00/2000	John Hancock Abbott Compound Summary Cholinergic Channel Modulator (ABT-594) 2000	JHII021620 - JHII021626			03/06/2008
543	543	05/26/2000	Cohen Email Forwarding Latest Proposed Terms Sheet	ABBT0008178 - ABBT0008181		No Objection	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
549	549	06/08/2000	Purchase Recommendation re: Pharma Marketing Ltd	JHII012376 - JHII012388	Blewitt_0010	No Objection	
550		06/20/2000	Klotz Email Preliminary Abbott Basket Analysis (Klotz 7)	JH003080 - JH002090	Klotz_0007		03/14/2008 (Tucker Affidavit)
551	551	06/27/2000	Klotz Email re: Materials for your Comments (Klotz 8)	JH003058 - JH003069	Klotz_0008	No Objection	
556		07/11/2000	Klotz Email re: Rest of Research Summaries (Klotz 11)	JH003014 - JH003026	Klotz_0011		03/05/2008
559		07/18/2000	Klotz Email re: First Neuropathic Pain Interview (Klotz 12)	JH002999 - JH003001	Klotz_0012		03/05/2008
560	560	07/21/2000	Klotz Email to Blewitt re: Moellering Interview (Blewitt 39)	JH002993 - JH002997	Blewitt_0039	No Objection	
561		07/23/2000	Klotz Email re: Questions for Abbott (Klotz 13)	JH002984 - JH002988	Klotz_0013		03/05/2008
562	562	07/28/2000	Klotz Email re: Abbott interview write-up	JH002973 - JH002979	Blewitt_0019	No Objection	
567	567	09/18/2000	Lee Email re: Abbott Hancock - Memo re: Research Funding Agreement (Lee 4)	JH003342 - JH003346	Lee_0004	No Objection	
568	568	09/18/2000	GBSA Spreads to On the run Treasuries 9/16 -9/25/2000	JHII021647 - JHII021649		No Objection	
569		09/21/2000	Purchase Recommendation re: Abbott Labs ("Non-Recourse")	JH001185 - JH001202	Blewitt_0015		03/14/2008 (Tucker Affidavit)
573	573	09/28/2000	Thomas Email re: ABT-594 M99-114 Slides for David (Thomas 14)	ABBT0051892 - ABBT0051904	Thomas_0014	No Objection	
580		11/20/2000	Fox Email re: FDA Telephone Contact Report ABT-773 (Leonard 51)	ABBT0558681 - ABBT0558683	Leonard_0051		03/11/2008 (Fox Affidavit)
582		11/27/2000	FDA Contact Report [ABT-773 End of Phase 2 Meeting] (Fox 5)	ABBT205257 - ABBT205259	Fox_0005		03/11/2008 (Leonard Affidavit)
586		00/00/2001	ASCO 2001 MMPI Update	ABBT0063643 - ABBT0063649			03/11/2008 (Leonard Affidavit)
587		01/00/2001	ABT-773 Project Status Report Monthly Highlights January 2001	ABBT0000302 - ABBT0000308			03/06/2008 (C. Meyer Affidavit)
591		01/25/2001	Dart memo re: APU Prioritization Meeting	ABBT0012433 - ABBT000012496			03/13/2008 (Hendricks Affidavit)
603	603	02/00/2001	ABT-594 Neuronal Nicotinic Receptor Agent February 2001	ABBT0000412 - ABBT0000417		No Objection	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
607		02/12/2001	Presentation re: ABT-773 Update February 12, 2001 (Meyer 10)	ABBT0576828 - ABBT0576871	Meyer_0010		03/11/2008 (Leonard Affidavit)
608		02/22/2001	Sun Email re: 773 Material	ABBT204959 - ABBT205279			03/06/2008 (C. Meyer Affidavit)
608A	P's IR	02/22/2001	Email from Eugene X. Sun to Stan Bukofzer re: 773 Material	ABBT204959 - 5046			03/11/2008
611	611	03/00/2001	Summary of Success Probabilities by Project and Franchise Portfolio Analysis March 2001	ABBT287552 - ABBT287557		No Objection	
612	612	03/00/2001	ABT-518 Matrix Metalloproteinase Inhibitor Monthly Status Project Report March 2001	ABBT0000349 - ABBT0000354		No Objection	
613		03/00/2001	ABT-773 Ketolide Antibiotic Tablet Monthly Status Project Report March 2001	ABBT0000429 - ABBT0000438			03/06/2008 (C. Meyer Affidavit)
614		03/00/2001	ABT-773 Agenda Presentation	ABBT271783 - ABBT271816			03/11/2008 (Bukofzer Affidavit)
616		03/02/2001	Russell Memo re: 2001 Plan Final Reference Package	ABBT0037509 - ABBT0037608			03/11/2008 (Leonard Affidavit)
617	617	03/06/2001	Silber Email re: ABT-594 - Purdue Response	ABBT0119894 - ABBT0119895		No Objection	
620		03/09/2001	ABT-594 Presentation re: Abbott Portfolio Review March 7-9, 2001	ABBT0048632 - ABBT00048645			03/11/2008 (Leonard Affidavit)
621		03/09/2001	Agenda for Portfolio Review Meeting March 7-9, 2001	ABBT0092919 - ABBT0092921			03/11/2008 (Leonard Affidavit)
622		03/09/2001	ABT-773 Craft Presentation re: Abbott Portfolio Review March 7-9, 2001	ABBT0013203 - ABBT0013214			03/06/2008 (C. Meyer Affidavit)
623	623	03/12/2001	D'Amico Email re: M00235 Patient	ABBT0059464 - ABBT0059464		No Objection	
624	624	03/12/2001	Adams Email re: Latest Version (Lee 18)	JH010033 - JH010142	Lee_0018	No Objection	
625		03/13/2001	Compound Summary for Cholinergic Channel Modulator ABT-594	JHII021612 - JHII021619			03/06/2008
627		03/13/2001	Compound Summary for Matrix Metalloproteinase Inhibitor MMPI Program ABT-518	JHII021607 - JHII021611			03/06/2008
629	629	03/14/2001	Rieser Email re: M00235 PK Validation	ABBT0060789 - ABBT0060789		No Objection	
631		03/19/2001	ABT-773 Update March 19, 2001 Presentation	ABBT120465.UR - ABBT120513.UR			03/06/2008 (C. Meyer Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
634	634	04/00/2001	ABT-518 Matrix Metalloproteinase Inhibitor Monthly Status Project Report April 2001	ABBT0000355 - ABBT0000360		No Objection	
635	635	04/00/2001	ABT-594 Neuronal Nicotinic Receptor Agent Monthly Status Project Report April 2001	ABBT0000491 - ABBT0000496		No Objection	
638		05/00/2001	ABT-773 Ketolide Antibiotic Tablet Monthly Status Project Report May 2001	ABBT0000508 - ABBT0000519			03/11/2008 (Bukofzer Affidavit)
639	639	05/02/2001	ABT-594 Phase 2B Diabetic Neuropathic Pain Results M99114 Study Review 05/02/2001 Presentation	ABBT0001769 - ABBT0001839		No Objection	
646	646	06/07/2001	MMPI Working Group Minutes 6/7/01 (Leonard 34)	ABBT0026340 - ABBT0026342		No Objection	
649		06/20/2001	C. Meyer Email re: ABT 773 Taisho/Abbott Meeting June 26 (Bukofzer 14)	ABBT229367 - ABBT229448	Bukofzer_0014		03/11/2008 (Bukofzer Affidavit)
651	651	06/21/2001	Nabulsi Letter re: ABT-518	ABBT0507879 - ABBT0507879		No Objection	
652	652	06/28/2001	GBSA Spreads to On the run Treasuries	JHII021462 - JHII021462		No Objection	
653	653	07/00/2001	ABT-594 Neuronal Nicotinic Receptor Agent Monthly Status Project Report July 2001	ABBT0000612 - ABBT0000618		No Objection	
654		07/00/2001	ABT-773 Ketolide Antibiotic Tablet Monthly Status Project Report July 2001	ABBT0000589 - ABBT0000598			03/11/2008 (Bukofzer Affidavit)
661	661	08/21/2001	ABT-594 GPEC Review August 21, 2001	ABBT311519 - ABBT311637	Meyer_0023; McCarthy_0054	No Objection	
663	663	09/17/2001	Deemer Email re: ABT-518 [Handling Out Licensing of ABT-518]	ABBT245619 - ABBT245619		No Objection	
667	667	10/00/2001	Center for Clinical Assessment Project Status Report October 2001	ST-AUDIT13231 - ST-AUDIT13235		No Objection	
670		11/26/2001	Pals Letter re: Research Funding Agreement Dated as of 03/13/01 - 2002 Preliminary Annual Research Plan (Hendricks 9)	JH000787 - JH000802	Hendrick_0009		03/14/2008 (Tucker Affidavit)
671	671	12/18/2001	Lyons Letter re: Research Funding Agreement Dated as of 03/13/01 2001 Program Status Report and Related Cost Summary - (Blewitt 44)	JH001065 - JH001068	Blewitt_0044	No Objection	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
672	672	12/31/2003	Journal Entries and Balance Sheet	JHII021496 - JHII021498		No Objection	
673		01/07/2002	Sun Memo re: PEC and ABT-773 Status	ABBT207773 - ABBT207775			03/11/2008 (Bukofzer Affidavit)
676		12/00/2002	January 2002 ABT-773 Presentation for Miles White	ABBT220665 - ABBT220672			03/11/2008 (Bukofzer Affidavit)
677	677	00/00/2003	Compound Summary Cholinergic Channel Modulator ABT-594 (Hair 24)	JHII021620 - JHII021626	Hair_0024	No Objection	
679	679	01/16/2003	Johansson Letter re: Research Funding Agreement Dated as of 03/31/01	ABBT0016048 - ABBT0016051		No Objection	
680	680	01/22/2003	Certificate Pursuant to Bond Investment Committee Guidelines Adopted 03/19/99	JH001105 - JH001105		No Objection	
682	682	03/14/2003	Welch Email re: FW: Abbott Labs Heads Up (Nastou_0010)	JH002447 - JH002447	Nastou_0010	No Objection	
688	688	12/19/2003	Investment Review Report re: Research Funding Agreement	JHII012075 - JHII012078		No Objection	
691	803	03/19/2004	Investment Review Report re: Research Funding Agreement	JHII012071 - JHII012074			03/05/2008
692		04/12/2004	Blewitt Letter re: Research Funding Agreement Dated 03/13/01 (Hair 1)	JHII011883 - JHII011886	Hair_0001		03/12/2008 (Campbell Affidavit)
693	693	06/23/2004	Desideri Letter re: Research Funding Agreement Dated 03/13/01	ABBT0000114 - ABBT0000114		No Objection	
698		09/13/2004	Investment Review Report re: Research Funding Agreement	JHII012067 - JHII012070			03/05/2008
701	701	11/05/2004	D'Amore Letter re: Research Funding Agreement Dated 03/14/01	ABBT0000137 - ABBT0000138		No Objection	
703	703	12/13/2004	License Agreement between Abbott and ALS	ABBT0027991 - ABBT0028015		No Objection	
704	704	12/13/2004	Investment Review Report re: Research Funding Agreement	JHII012062 - JHII012066		No Objection	
709	709	03/09/2005	John Hancock Abbott Research Funding Agreement Audit MH Notes 03/09/05	JHII021636 - JHII021636		No Objection	
710	710	03/11/2005	John Hancock/Abbott Summary of Available Monthly Project Status Reports as of 03/11/05	JHII021637 - JHII021637		No Objection	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
712		03/16/2005	Summary of Available Monthly Project Status Reports as of 03/16/05	JHII021644 - JHII021644			03/06/2008
715		03/22/2005	Campbell Email re: Hancock Audit	ABBT0126575 - ABBT0126575			03/12/2008 (Campbell Affidavit)
719	719	06/13/2005	Investment Review Report re: Research Funding Agreement	JHII012079 - JHII012083		No Objection	
722	722	02/06/2006	Hancock's Responses and Objections to Abbott's 1st Set of Interrogatories (Martinez 7)		Martinez_0007	No Objection	
723	723	00/00/0000	Electronic version of Monte Carlo Simulation (Excel spreadsheet) produced by John Hancock			No Objection	
724	724	00/00/0000	Electronic version of StoneTurn Index (Excel spreadsheet) titled John Hancock-Documents Index			No Objection	
724A		00/00/0000	StoneTurn Index (Excel spreadsheet) titled John Hancock-Documents Index				03/06/2008
725A		03/00/2001	ABT-594 Neuronal Nicotinic Receptor Agent, March 2001	ST-AUDIT08798 - ST-AUDIT08803			03/06/2008
725B		01/28/2002	Pharmaceutical Products R&D Global Delivery Expense Report	ST-AUDIT10946 - ST-AUDIT10960			03/06/2008
725C	Admitted as 175C but should be 725C	12/05/2000	ABT-773 Portfolio Review, Dec. 5, 2000	ST-AUDIT03137 - ST-AUDIT03243			03/06/2008
726	726	00/00/2001	McKinsey Project Map - 2001	MCK00533-539	Hopfield_0014	No Objection	
727	727	03/16/2001	Nabulsi and Janus Letter re: M00-235	ABBT0033105		No Objection	
728	728	03/16/2001	Nabulsi and Janus Letter re: M00-235	ABBT0033117		No Objection	
729	729	03/16/2001	Nabulsi and Janus Letter re: M00-235	ABBT0033118		No Objection	
730	730	05/12/2001	ASCO News Release titled, "Nearly 25,000 Cancer Specialists Meet in San Francisco for ASCO Annual Meeting"			No Objection	
732		06/25/2007	Advanced Life Sciences Form 8-K for the period of June 21, 2007				03/11/2008 (Bukofzer Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
738	738	09/16/2005	District Court's Memorandum and Order granting Hancock's Motion For Summary Judgment			No Objection	
740	740	05/10/2006	Hancock's Supplemental Responses To Abbott's Interrogatories Nos. 5(c), 5(d), 6(c), 6(d), and 10			No Objection	
741	741	06/23/2006	Hancock's Responses and Objections to Abbott's 2nd Set of Interrogatories			No Objection	
742	742	09/28/2006	First Circuit Court of Appeal's decision affirming the District Court's Order			No Objection	
743	743	04/30/2007	Hancock's Responses and Objections to Abbott's 3rd Set of Interrogatories			No Objection	
746	746	07/16/2007	Hancock's Supplemental Responses to Abbott Interrogatory Nos 2, 3, 5(A)(B)(F), 6(A)(B)(F), and 7			No Objection	
748		02/02/2001	Project Review ABT-089 and ABT-594	ABBT0002314 - ABBT0002469	Leonard_0036; Collicot_0032		03/11/2008 (Leonard Affidavit)
749		12/21/2000	Comilla Memo re: 2001 Plan Assumption Memo - Pass III	ABBT112987.ur - ABBT112992.ur			03/11/2008 (Leonard Affidavit)
750		01/29/2001	Portfolio Analysis January 2001 Review Reference Materials	ABBT0012369 - ABBT0012387			03/04/2008
755		05/04/2001	Abbott Oncology - Global Pharmaceutical R & D Strategy Retreat May 2-4, 2001	ABBT0060730 - ABBT0060767			03/11/2008 (Leonard Affidavit)
756		11/09/2001	Interoffice Memorandum re: Monthly Highlights October 2001	ABBT0003478 - ABBT0003481			03/11/2008 (Leonard Affidavit)
759		01/26/2001	Analgesia Venture 2001 Plan Revised 1/26/01	ABBT144630.ur - ABBT144646.ur	Leonard_0021		03/11/2008 (Leonard Affidavit)
760		12/10/2001	Summary of 12/10/2001 PEC Meeting	ABBT209487 - ABBT209488	Leonard_0044		03/11/2008 (Leonard Affidavit)
761		01/07/2002	Interoffice correspondence re: summary on development status of ABT-773	ABBT0559668 - ABBT0559670	Leonard_0049		03/11/2008 (Leonard Affidavit)
762		11/27/2000	Memorandum re: Meeting Minutes	AUDIT 002817 - AUDIT 002829			03/11/2008 (Leonard Affidavit)
768		01/28/2005	D'Amore Letter re: Research Funding Agreement Dated 03/13/01	ABBT0000167 - ABBT0000168			03/12/2008 (Campbell Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW
Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
773	773	9/28/2001	ABT518 Selective Matrix Metalloproteinase MMP Inhibitor	ABBT0014648 - ABBT00146657		No Objection	
774	774	09/00/2001	ABT-518 Matrix Metalloproteinase Inhibitor	ABBT0000381 - ABBT0000388		No Objection	
776	776	07/02/2001	Kowaluk Email re: Final 07/03/2001 Update	ABBT290799 - ABBT290837		No Objection	
780		11/29/2000	Fox Email re: Slides for 12/5 Leiden meeting	ABBT0556816 - ABBT0556822	Fox_0004		03/11/2008 (Fox Affidavit)
781		11/28/2000	Fox Email re: Executive Summary of ABT-773 End-of-Phase 2 Mtg w/FDA	ABBT0558150	Fox_0006		03/11/2008 (Fox Affidavit)
782		03/07/2001	Abbott Portfolio Review March 7-9, 2001, ABT-518	ABBT0064316 - ABBT0064330			03/11/2008 (Leonard Affidavit)
784		08/21/2001	ABT-594 Pharma Executive Management Committee Review	ABBT0184372 - ABBT0184496	Leiden_0032		03/12/2008 (Leiden Affidavit)
786		01/28/2002	Pharmaceutical Products R&D Global Discovery Project Expense Report	ABBT0578006 - ABBT0578015			03/13/2008 (Stiles Affidavit)
787		12/05/2000	ABT773 Portfolio Review 12/05/2000	ABBT205088 - ABBT205256			03/11/2008 (Leonard Affidavit)
788		07/25/2001	ABT773 Dosing Options 07/25/2001	ABBT119362.ur - ABBT119446.ur			03/06/2008 (C. Meyer Affidavit)
789		10/00/2001	Monthly Status Project Report for ABT773 Ketolide Antibiotic Tablet, October 2001	ABBT0000726 - ABBT0000735			03/06/2008 (C. Meyer Affidavit)
790		03/00/2002	Monthly Status Project Report for ABT773 Ketolide Antibiotic Tablet, March 2002	ABBT0000962 - ABBT0000971			03/06/2008 (C. Meyer Affidavit)
791	791	00/00/2001	Plan Assumption Memo Pass 3	ABBT112985.ur - ABBT112992.ur; ABBT112995.ur - ABBT112999.ur; ABBT113015.ur - ABBT113018.ur; ABBT113026.ur - ABBT113029.ur	Woidat_0009	No Objection	
793		05/12/2001	Abstracts from 2001 ASCO Annual Meeting	ABBT0556350 - ABBT0556356			03/11/2008 (Leonard Affidavit)
794	794	00/00/0000	John Hancock Abbott Laboratories Research and Development Transaction Investment Analysis Report	JH002424 - JH002429	Blewitt_0012	No Objection	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
795		07/31/2001	Clinical Study Report No. R&D/01/171 ABT-594 Protocol M99-114	ABBT0065982 - ABBT0066097			03/12/2008 (Rodda Affidavit)
798		04/20/2004	Wittenberg Email re: Meeting for Hancock Audit with Wittenberg, Stiles, and Potthoff	ABBT0036399 - ABBT0036399; ABBT0008949 - ABBT0008949	Campbell_0003		03/12/2008 (Campbell Affidavit)
799		06/22/2001	Bukofzer Email re: attaching Final Copy of 773 Decision Analysis	ABBT203851 - ABBT203894	Bukofzer_0015		03/11/2008 (Fox Affidavit)
800		03/00/2001	Summary of Success Probabilities by Project and Franchise Portfolio Analysis (March 2001)	ABBT0047890 - ABBT0047892			03/10/2008
801		04/20/2001	Portfolio Analysis of 2001 Abbott Global Pharmaceutical Development Assets	ABBT0013874 - ABBT0013946			03/10/2008
802	802	03/24/1999	Purchase Recommendation for Idun Pharmaceuticals Inc. (Klotz 6)	JHII012355 - JHII012367	Klotz_0006	No Objection	
803	Marked as 691 on 3/5/08	07/03/2000	Klotz Email re: Update on Cytostatic Area (Klotz 9)	JH003032 - JH003057	Klotz_0009		03/03/2008
804	804	07/11/2000	Klotz Email re: Edit of Neuropathic Pain Summary (Klotz 14)	JH003007 - JH003013	Klotz_0014	No Objection	
807	807	02/00/2001	ABT-773 Descriptive Memorandum February 2001 (Klotz 19)	JH008153 - JH008209	Klotz_0019	No Objection	
809	809	00/00/2000	Pub Med Abstracts re: ABT- 773 (Klotz 21)	JH002212 - JH002226	Klotz_0021	No Objection	
812	812	03/07/2000	Agreement re: Proposed Summary of Terms (Nastou 1)	JH002308 - JH002311	Nastou_0001	No Objection	
815	815	09/21/2000	Bond Investment Committee Meeting Minutes (Nastou 7)	JH005573 - JH005573	Nastou_0007	No Objection	
817	817	09/30/2002	Blewitt Email forwarding the latest model re: Abbott Labs (Blewitt 13)	JH003142 - JH003158	Blewitt_0013	No Objection	
818		07/11/2000	Klotz Email attaching research summaries (Blewitt 17)	JH003014 - JH003026	Blewitt_0017		03/03/2008
821	821	06/05/2000	ABT-773 Descriptive Memorandum 05/00/2000 (Blewitt 32)	ABBT246466 - ABBT246471	Blewitt_0032	No Objection	
822	822	00/00/0000	List of Questions for Interviewees re: ABT-773 (Blewitt 38)	JH000655 - JH000658	Blewitt_0038	No Objection	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
823	823	07/21/2000	Klotz Email Moellering Interview (Blewitt 39)	JH002993 - JH002997	Blewitt_0039	No Objection	
824	824	07/28/2000	Klotz Email re Abbott Interview Writeup (Blewitt 41)	JH002973 - JH002979	Blewitt_0041	No Objection	
830	830	09/23/2002	Kirkpatrick Email re: Status of JH Compounds Divestment Activities (Nisen 37)	ABBT334838 - ABBT334841	Nisen_0037	No Objection	
831	831	05/22/2001	Nisen Email re: ABT-518 Summary of Findings on MMPI (Nisen 38)	ABBT0064226 - ABBT0064226	Nisen_0038	No Objection	
832	832	05/28/2001	Bronson Email re: ABT-518 Slides Whoops (Nisen 39)	ABBT0033486 - ABBT0033494	Nisen_0039	No Objection	
833	833	06/11/2001	Nisen Email re: MMPI Data from Subject X Additional Info (Nisen 40)	ABBT0063625 - ABBT0063626	Nisen_0040	No Objection	
834	D_BD	09/29/2004	Affidavit of Stephen J. Blewitt (Blewitt 21)		Blewitt_0021		03/03/2008
835	P's HZ	09/13/2000	E-mail from Gregory Bosco to Carol S. Meyer re: ABT-773 Dev. Plan	ABBT0557552 - 57			03/06/2008
836	D_A	11/00/2000	Cohen Memo Attaching Diligence and Research Plan Documents	ABBT0006627 - ABBT0006700			03/11/2008 (Leonard Affidavit)
837	D_AL	09/20/2001	C. Meyer Email thread re: Portfolio issues update	ABBT203477 - ABBT203484			03/11/2008 (Leonard Affidavit)
838	D_DB	12/11/2000	Calendar Entry Meeting ABT- 594 Power Calculations with Silber, Morris, Leonard	ABBT0125549			03/11/2008 (Leonard Affidavit)
839	D_DF	10/05/2001	Leonard Email re: New Agenda for Monday's PEC Meeting	ABBT224537 - ABBT224539			03/11/2008 (Leonard Affidavit)
840	D_DG	10/05/2001	Chiozzi Email re: October 8 program	ABBT0111238 - ABBT0111240			03/11/2008 (Leonard Affidavit)
841	D_DH	10/08/2001	Interoffice memorandum re: Monthly Highlights - September 2001	ABBT334009 - ABBT334011			03/11/2008 (Leonard Affidavit)
842	D_DN	04/27/2001	Interoffice Memorandum re: Monthly Highlights April 2001	ABBT143066.ur - ABBT143067.ur			03/11/2008 (Leonard Affidavit)
843	D_DO	08/10/2001	Interoffice Memorandum re: Monthly Highlights July 2001	ABBT0003466 - ABBT0003467			03/11/2008 (Leonard Affidavit)
844	D_DQ	01/09/2002	Calendar Entry Meeting ABT- 773 Presentation	ABBT0569033			03/11/2008 (Leonard Affidavit)
845	D_DR	02/08/2002	Interoffice Memorandum re: Monthly Highlights January 2002	ABBT247733 - ABBT247737			03/11/2008 (Leonard Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
846	D_DS	04/09/2002	Interoffice Memorandum re: Monthly Highlights March 2002	ABBT103547.ur - ABBT103551.ur			03/11/2008 (Leonard Affidavit)
847	D_DT	01/18/2001	Nisen Email re: Goodwin Philanthropy	ABBT0064814 - ABBT064817			03/11/2008 (Leonard Affidavit)
848	D_FC	01/20/2003	Pharmaceutical Products R&D Global Discovery Project Expense Report	ABBT0578016 - ABBT0578022			03/11/2008 (Leonard Affidavit)
849	D_FI	05/00/2001	ASCO Poster re : Phase 2 Study of the Matrix Metalloprotease Inhibitor Prinomastat in Patients with Progressive Breast Cancer	ABBT0556331 - ABBT0556331			03/11/2008 (Leonard Affidavit)
850	D_FK	05/12/2001	Abstracts from Proceedings of ASCO Volume 20, 2001	ABBT0556332 - ABBT0556333			03/11/2008 (Leonard Affidavit)
852	D_Y	03/13/2001	Research Funding Agreement between Abbott Laboratories and John Hancock Life Insurance	JH008074 - JH008211			03/11/2008 (Leonard Affidavit)
853	D_AC	04/27/2001	Fox Email re: FYI Ketek	ABBT110591.ur - ABBT110591.ur			03/11/2008 (Bukofzer Affidavit)
854	D_BS	06/11/2007	Crain's Chicago Business Article titled, "Waiting to Exhale. Day of Reckoning nears as biotech firm Advanced Life awaits trial results on new treatment for pneumonia" by Mike Colias				03/11/2008 (Bukofzer Affidavit)
855	D_BU	06/29/2007	Crain's Chicago Business Article titled, "Waiting to Exhale. Clinical Trials" by Mike Colias				03/11/2008 (Bukofzer Affidavit)
856	D_BX	08/21/2007	Life Science Weekly Article titled, "Reports from Advanced Life Sciences Holdings describe recent developments"				03/11/2008 (Bukofzer Affidavit)
857	D_FT	07/23/2001	ABT-773 Presentation	ABBT103191.ur - ABBT103270.ur			03/11/2008 (Bukofzer Affidavit)
859	D_BW	02/13/2001	U.S. Food and Drug Administration Center for Drug Evaluation and Research Web Page Article titled, "Drug-Induced Liver Toxicity"				03/11/2008 (Fox Affidavit)
860	D_EC	12/00/2001	December 2001 PEC Presentation re ABT-773	ABBT120514.ur - ABBT120558.ur			03/12/2008 (Leiden Affidavit)
861	D_BN	10/13/2006	Expert Report of Dr. Bruce Rodda		Rodda_0003		03/12/2008 (Rodda Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
862	D_BR	02/26/2007	Expert Report of Dr. Bruce Rodda (Statistical Issues)		Rodda_0002		03/12/2008 (Rodda Affidavit)
863	D_FD	12/00/2002	Comprehensive Project Accounting System DINGII Project Detail 12/00/2002	ABBT0578023 - ABBT0578025			03/13/2008 (Stiles Affidavit)
864	D_FE	06/07/2004	Global Pharmaceutical Research and Development Global Development Project Expense Report Site Global All Sites 12/00/2003	ABBT0578026 - ABBT0578031			03/13/2008 (Stiles Affidavit)
865	D_FF	01/14/2005	Global Pharmaceutical Research and Development Global Development Project Expense Report Site Global All Sites - 12/00/2004	ABBT0578032 - ABBT0578035			03/13/2008 (Stiles Affidavit)
866	D_FG	12/00/2005	Global Pharmaceutical Research and Development Global Development Project Expense Report Site Global All Sites - 12/00/2005	ABBT0578036 - ABBT0578038			03/13/2008 (Stiles Affidavit)
867	D_EF	08/22/2001	Deemer Email re: outlicensing opportunities attaching introductory slides	ABBT246353 - ABBT246368			03/13/2008 (Deemer Affidavit)
868	D_EG	09/28/2001	Deemer Email re: Deemer Weekly Update	ABBT246248 - ABBT24652			03/13/2008 (Deemer Affidavit)
869	D_EH	10/12/2001	Deemer Email re: Licensing opportunities	ABBT246369			03/13/2008 (Deemer Affidavit)
870	D_EI	10/26/2001	Rosenthal Email re: ABT-518 and hematological cancer	ABBT0086829			03/13/2008 (Deemer Affidavit)
871	D_EL	04/03/2002	Hoff-Velk Email re: Salmedix ABT-518	ABBT0170011 - ABBT0170014			03/13/2008 (Deemer Affidavit)
872	D_EM	04/06/2002	ABT-518 Selective Matrix Metalloproteinase MMP Inhibitor - Abbott/Salmedix Collaboration	ABBT0141755 - ABBT0141772			03/13/2008 (Deemer Affidavit)
873	D_EN	04/16/2002	Hoff-Velk Email re: Salmedix Forwarding Jerry's Note	ABBT0089655			03/13/2008 (Deemer Affidavit)
874	D_EO	05/03/2002	Poulos Email re: April highlights	ABBT0542887 - ABBT0542892			03/13/2008 (Deemer Affidavit)
875	D_EP	08/02/2002	Fitzgerald Email re: ABT-518 Outlicense Status	ABBT0086988			03/13/2008 (Deemer Affidavit)
876	D_EQ	08/13/2002	Nabulsi Email re: John Hopkins Cancer Center and Abbott Oncology Collaboration Meeting	ABBT0169420 - ABBT0169421			03/13/2008 (Deemer Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
877	D_ER	08/14/2002	Presentation to Johns Hopkins re: ABT-518 Selective Matrix Metalloproteinase MMP Inhibitor	ABBT0141711 - ABBT0141728			03/13/2008 (Deemer Affidavit)
878	D_ES	09/24/2003	Hoff-Velk Email re: ABT-518 and Prospective Licensee	ABBT0091538 - ABBT0091539			03/13/2008 (Deemer Affidavit)
879	D_ET	02/20/2004	Asia Trip Report, Feb. 16-20, 2004, Perry Nisen	ABBT0167630 - ABBT0167638			03/13/2008 (Deemer Affidavit)
880	D_EU	05/25/2004	Davidsen Email re: ABT518 Negative Clinical Results with AG3340 and Marimastat	ABBT0089550 - ABBT0089551			03/13/2008 (Deemer Affidavit)
881	P's AF	03/22/2001	Email from Philip M. Deemer to Perry D. Nisen re: Hancock and Alcon	AL000403			03/13/2008 (Deemer Affidavit)
882	D_BI	12/06/2005	Investment Review Report re: Research Funding Agreement	JHII012050 - JHII012055			03/14/2008 (Tucker Affidavit)
883	D_BP	01/19/2007	Expert Report of Avram S. Tucker		Tucker_0002		03/14/2008 (Tucker Affidavit)
884	D_BY	12/03/2007	Supplemental Expert Report of Avram S. Tucker				03/14/2008 (Tucker Affidavit)
885	D_FU	02/08/2002	Turner Email attaching year end reports	ABBT0027417 - ABBT0027432			03/14/2008 (Tucker Affidavit)
886	D_FW	03/05/2003	Mangan Email re: February Early Warning Projection	JH002419 - JH002420			03/14/2008 (Tucker Affidavit)
887	D_FX	02/27/2006	Hancock Loan Review Report	JHII021946 - JHII021948			03/14/2008 (Tucker Affidavit)
888	D_FY	08/00/2004	Moody Rating Symbols & Definitions				03/14/2008 (Tucker Affidavit)
889	D_GD	10/23/2007	Supplemental Affidavit of Keith Hendricks dated October 23, 2007				03/14/2008 (Tucker Affidavit)
890	D_GO	00/00/0000	ABT-751 Commercial Forecast	ABBT0003252 - ABBT0003254			03/14/2008 (Tucker Affidavit)
891	D-GP	02/17/2008	Schedule 1A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case				03/14/2008 (Tucker Affidavit)
892	D_GQ	02/17/2008	Schedule 1B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case				03/14/2008 (Tucker Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
893	D_GR	02/17/2008	Schedule 2A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case				03/14/2008 (Tucker Affidavit)
894	D_GS	02/17/2008	Schedule 2B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case				03/14/2008 (Tucker Affidavit)
895	D_GT	02/17/2008	Schedule 3A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case				03/14/2008 (Tucker Affidavit)
896	D_GU	02/17/2008	Schedule 3B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case				03/14/2008 (Tucker Affidavit)
897	D_GV	02/17/2008	Schedule 4A illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Low Case				03/14/2008 (Tucker Affidavit)
898	D_GW	02/17/2008	Schedule 4B illustration of Impact of Selected Errors in Mr. Friedman's Lost Royalties and Milestone Payment Calculation - Base Case				03/14/2008 (Tucker Affidavit)
899	D_GX	02/17/2008	Schedule 5A and 5B Illustration of Change in Currently Expected Royalties - Low Case and Base Case				03/14/2008 (Tucker Affidavit)
900	D_GY	02/17/2008	Schedule 6A Calculation of 1/3 of Unspent Aggregate Carryover Amount and Schedule 6B Abbott's Reported Program Spending by Compound				03/14/2008 (Tucker Affidavit)

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
901	D_GZ	02/17/2008	Schedule 7A Abbott Reported Spending in 2001, Schedule 7B 2002 Annual Research Plan, Schedule 7C Calculation of Expected/Nominal Ratio and Schedule 7D "Risk Adjusted" 2002 Preliminary Annual Research Plan				03/14/2008 (Tucker Affidavit)
902	D_FP	05/01/2000	Klotz Letter re: General Biotechnology and Pharmaceutical Investments Consulting (Klotz 1)	JH001691 - JH001693	Klotz_0001	No Objection	
903	D_FX	02/27/2006	Hancock Loan Review Report	JHII021946 - JHII021948		No Objection	
904	D_FZ	11/25/2007	ALS Press Release identified as Exhibit 99.1 to Advanced Life Sciences Form 8-K for the period of November 15, 2007			No Objection	
905	D_GI	08/10/2001	Davidson Memo Results from the ABT-518 Clinical Trial, and ASCO 2001 Update (Nisen 31)	ABBT0049970 - ABBT0049977; ABBT0064227-ABBT0064233	Nisen_0031	No Objection	
906	D_GK	10/29/1999	Abbott Laboratories ABT-594 Investigational New Drug IND Annual Report (Collicott 4)	ABBT335520 - ABBT335570	Collicott_0004	No Objection	
907	D_GN	04/23/2001	M99114 Study Review Presentation (Collicott 39)	ABBT0001749 - ABBT0001758	Collicott_0039	No Objection	
908	D_HB	03/23/2007	John Hancock's Objections and Responses to Abbott Laboratories First Set of Interrogatories in Re John Hancock Life Insurance Co et al vs Abbott Laboratories (Davis 2)		Davis_0002	No Objection	
909	D_HM	07/19/2004	Campbell Email re: Hancock Audit (Martinez 3)	ABBT0000265 - ABBT0000266	Martinez_0003	No Objection	
910	D_HN	08/31/2004	Campbell Email re: John Hancock Audit (Martinez 5)	ABBT0000257 - ABBT0000260	Martinez_0005	No Objection	
911	D_HO	10/26/2004	Campbell Email re: Status on Documents Available for Review (Martinez 6)	ABBT0000250 - ABBT0000253	Martinez_0006	No Objection	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
912	D_HP	03/15/2005	Campbell Email re: JH Abbott Audit Documentation (Martinez 9)	ABBT0000280 - ABBT0000284	Martinez_0009	No Objection	
913	D_HQ	03/17/2005	John Hancock Document Index Report (Martinez 10)	JHII021526 - JHII021594	Martinez_0010	No Objection	
914	D_HR	03/11/2005	Summary of Available Monthly Project Status Reports as of 03/11/2005 (Martinez 19)	JHII021637 - JHII021643	Martinez_0019	No Objection	
915	D_HV	00/00/2003	Compound Summary Dopamine Receptor Agonist Program ABT-724 Report (Martinez 23)	JHII021627 - JHII021635	Martinez_0023	No Objection	
916	D_HX	03/22/2005	Hair Email re: JH Abbott Audit Documentation (Hair 4)	ABBT0000273 - ABBT0000276	Hair_0004	No Objection	
917	D_HY	04/05/2005	Davis Email re John Hancock/Abbott audit issues (Hair 2)	ABBT0000215 - ABBT0000220	Hair_0002	No Objection	
918	D_HZ	03/18/2005	Hair Email re: JH Abbott Audit Documentation (Hair 5)	ABBT0000277 - ABBT0000279	Hair_0005	No Objection	
919	D_IC	06/27/2000	Proposed Summary of Terms Agreement (Lee 1)	AL000115 - AL000119	Lee_0002	No Objection	
920	D_ID	08/17/2000	Deemer Email re: Draft Agreement (Lee 3)	AL000138 - AL000175	Lee_0003	No Objection	
921	D_II	04/19/2000	Email re: More Model	JH003561 - JH003561	Hartz_0011	No Objection	
922	D_IM	03/26/2002	Email re: Abbott Labs	JH002659 - JH002659	Hartz_0026	No Objection	
923	D_IO	03/27/2003	Email memo re: Abbott Laboratories Research and Funding Agreement	JH002407 - JH002409	Hartz_0032	No Objection	
924	D_IP	06/11/2003	Email re: Abbott Research and Development Agreement	JH003113 - JH003115	Hartz_0037	No Objection	
925	D_IQ	06/17/2003	Email and Report re: Abbott Valuation	JH003107 - JH003112	Hartz_0038	No Objection	
926	D_IR	12/19/2003	Email re: John Hancock vs. Abbott Laboratories	JH004479 - JH004480	Hartz_0039	No Objection	
927	D_IS	02/24/2005	Email re: Abbott	JHII011221 - JHII011221	Hartz_0045	No Objection	
928	D_LB	01/18/2005	Martinez Email re: Audit Thursday (Martinez 8)	ABBT0000235 - ABBT000023	Martinez_0008	No Objection	
929	D_LE	05/20/2001	Nisen Email re: MMPI Summary of ASCO Studies (Nabulsi 25)	ABBT0064234 - ABBT0064234	Nabulsi_0025	No Objection	
930	D_LF	05/12/2001	Compilation of ASCO documents (Nabulsi 27)	ABBT0556321 - ABBT0556349	Nabulsi_0027	No Objection	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
931	D_LH	08/10/2001	Davidsen Report re: ABT518 (Nabulsi 34)	ABBT0049970 - ABBT0049977	Nabulsi_0034	No Objection	
932	D_LK	03/28/2005	Report of Documents that were Received by Stone Turn but not Identifiable or Previously Included in the Document Index (Hair 13)	JHII021598 - JHII021598	Hair_0013	No Objection	
933	D_LO	03/18/2005	Report of John Hancock Abbott Summary of Available Monthly Highlights (Hair 19)	JHII021638 - JHII021643	Hair_0019	No Objection	
934	D_LV	09/19/2000	Hartz Email re: Abbott Modeling the Expect Returns and Expected Loss Report (Blewitt 14)	JH003551 - JH003555	Blewitt_0014	No Objection	
935	D_LX	04/01/2005	Faxed letter re: Research Funding Agreement dated as of 03/13/2001 (Blewitt 28)	JHII011911 - JHII011915	Blewitt_0028	No Objection	
936	D_LY	01/11/2001	MMPI Working Group Meeting Minutes dated 01/11/2001 (Loberg 3)	ABBT0045264 - ABBT0045269	Loberg_0003	No Objection	
937	D_LZ	05/11/2001	Oncology Status Report as of 05/11/2001 (Loberg 10)	ABBT0045302 - ABBT0045304	Loberg_0010	No Objection	
938	D_MH	04/00/2001	Excerpts from 2001 April Update GPRD	ABBT0011531-ABBT0011532; ABBT0011547-ABBT0011548		No Objection	
939	D_BH	09/06/2005	Blewitt Memo re: Report Request # 85 (FOLLOW-UP) - Valuation of Sch BA Part 1 Assets Abbott Laboratories (Blewitt 30)	JHII012056 - JHII012061	Blewitt_0030	No Objection	
940	D_BZ	12/12/2003	Complaint in <i>Hancock Life Ins. Co., et al. v. Abbott Laboratories</i> , No. 03-12501 (<i>Hancock I</i>)			No Objection	
941	D_CP	06/23/2006	Supplemental Complaint		Friedman_0002	No Objection	
942	D_CS	12/29/2006	First Amended Supplemental Complaint			No Objection	
943	D_GH	12/20/2002	Letter re: research Funding Agreement Dated as of 03/13/2001 (Blewitt 43)	JH000807 - JH000817	Blewitt_0043	No Objection	
944	D_LI	01/08/2001	Collicott Email re: M99114 Crf Tracking (Collicott 28)	ABBT240624 - ABBT240624	Collicott_0028	No Objection	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
945	D_LS	09/21/2000	John Hancock Purchase Recommendation for Abbott Laboratories (Non-Recourse) (Blewitt 30)	JH002373-JH002390	Blewitt_0030		
[946]	D_C	07/11/2002	Bukofzer Email re: ABT 773 Communication	ABBT203446 - ABBT203450		Hearsay (ABBT203446-48 ONLY)	
[947]	D_H	00/00/2000	DePonti, Poluzzi & Montanero Article titled "QT Interval Prolongation by Non Cardiac Drugs Lessons to be Learned from Recent Experience"		Klotz_0030	Hearsay	
[948]	D_I	05/09/2000	Collicott Email re: Resume	ABBT242357 - ABBT242361	Collicut_0001	Hearsay / Irrelevant / Authenticity	
[949]	D_L	07/00/2000	Research Analysis Report by Wiqar Shaik Titled, "The Changing Face of Antihistamines and Cardiac Adverse Drug Reactions: A Clinical Perspective"		Klotz_0028	Hearsay / Irrelevant	
[950]	D_M	08/11/2000	MedWatch Summary of Safety Related Drug Labeling Changes Approved by FDA June 2000		Klotz_0029	Hearsay / Irrelevant	
[951]	D_Q	11/01/2000	Torney Email re: Funding Agreement	JH003740 - JH003814		Irrelevant	
[952]	D_AD	05/04/2001	Hansen Email re: Marimastat	ABBT0054230 - ABBT0054231		Hearsay	
[953]	D_AJ	08/06/2001	Davidsen Email to Nisen re: ABT-518 [Marimastat Shows Promise as Treatment for Unresectable Pancreatic Cancer]	ABBT0049990 - ABBT0049990		Hearsay	
[954]	D_AK	08/16/2001	Kowaluk Email re: ABT-594 DSG Slides for PEMC Review (McCarthy 53)	ABBT289332 - ABBT289344	McCarthy_0053	Objection Withdrawn	
[955]	D_AM	10/02/2001	Leonard Memo re: 10/08 PEC Meeting Agenda	ABBT201003 - ABBT201007	McCarthy_0057	Objection Withdrawn	
[956]	D_AP	08/06/2002	Lyons Email re: ABT-773	ABBT333998 - ABBT333998		Hearsay	
[957]	D_AS	12/06/2002	Tyree Memo re: November 2002 Highlights	ABBT0518032 - ABBT0518034		Objection Withdrawn	
[958]	D_AT	12/20/2002	Johansson Letter re: Research Funding Agreement Dated as of 03/31/01	JH009977 - JH009978		Objection Withdrawn	
[959]	D_AV	02/28/2003	Mathers Memo+D315 re: February Highlights	ABBT335048 - ABBT335050		Hearsay	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
[960]	D_AW	11/12/2003	Tyree Letter re: Research Funding Agreement Dated 03/13/01	ABBT0004519 - ABBT0004520		Used in Settlement Discussions and inadmissible under Fed. R. Evid. 408/Hearsay	
[961]	D_AX	00/00/2004	Hancock Program Funding Scenarios (Work Paper)	CRA00127 - CRA00139		Hearsay	
[962]	D_BE	10/27/2004	Johansson Letter re: Research Funding Agreement Dated as of 03/31/01	JHII011289 - JHII011291		Hearsay	
[963]	D_CL	11/07/2005	Abbott's Response to Hancock's First Request for Production of Documents			Hearsay/Irrelevant	
[964]	D_CM	11/28/2005	D'Amore Letter re: Hancock v. Abbott, Case No. 05-11150-DPW			Hearsay	
[965]	D_CN	12/09/2005	D'Amore Letter re: Hancock v. Abbott, Case No. 05-11150-DPW			Hearsay	
[966]	D_CR	12/06/2006	Transcript of Hearing before Honorable Douglas P. Woodlock			Hearsay	
[967]	D_DD	08/16/2001	Interoffice memorandum re: ABT-594 Review, August 21, 2001, Pharmaceutical Executive Management Committee	ABBT0048631		Hearsay	
[968]	D_DK	02/14/2003	Out-license Anti-infective Compounds Board Document February 14, 2003 Draft 8	ABBT0009617 - ABBT0009618		Authenticity / Hearsay	
[969]	D_DL	03/27/2001	Kowaluk Email re: therapeutic strategy evaluations attaching briefing document portfolio review	ABBT327314 - ABBT327327		Hearsay (ABBT327316-27)	
[970]	D_DP	10/08/2001	Interoffice Memorandum re: Monthly Highlights September 2001	ABBT0003482 - ABBT0003484		Hearsay	
[971]	D_DW	03/30/2004	Transcript of March 30, 2004 Hearing in Hancock I			Hearsay	
[972]	D_EW	04/09/2001	Kowaluk Email re: Portfolio Probabilities	ABBT285535 - ABBT285536		Hearsay	
[973]	D_FM	11/03/2000	Davidsen Email re: JCO paper on Bayer compound	ABBT0057776 - ABBT0057777; ABBT0057787 - ABBT0057843		Multiple Documents / Hearsay	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
[974]	D_FN	03/05/2001	Drug document compound details for Marimastat	ABBT0026863 - ABBT0026866		Hearsay	
[975]	D_FQ	02/05/2001	McCarthy Email re: DSG with reply by Kowaluk (McCarthy 38)	ABBT328810 - ABBT328812	McCarthy_0038	Hearsay	
[976]	D_FR	10/23/2001	McCarthy Email re: Non Confidential Briefing on ABT-594 (McCarthy 61)	ABBT246791 - ABBT246792	McCarthy_0061	Hearsay	
[977]	D_GE	10/17/2000	Draft Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co Dated as of 10/00/2000 (Blewitt 22)	AL000481 - AL000521	Blewitt_0022	Irrelevant	
[978]	D_GF	03/00/2001	Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co Dated as of 03/00/2001 (Blewitt 23)	AL001323 - AL001377	Blewitt_0023	Irrelevant	
[979]	D_GG	05/11/2000	Ketek Profile Report (Blewitt 36)	JH000747 - JH000761	Blewitt_0036	Objection Withdrawn	
[980]	D_GJ	04/10/2001	Redenbach - Mueller Email re: Fw Pharma Strategy Retreat Virus Checked (Hopfield 23)	ABBT294218 - ABBT294247	Hopfield_0023	Hearsay (ABBT294218-20)	
[981]	D_GM	01/18/2001	Collicott Email re: ABT-594 Completion of Study for Neuropathic Pain (Collicott 30)	ABBT240417 - ABBT240417	Collicott_0030	Hearsay	
[982]	D_HA	03/23/2007	Rule 30b6 Notice of Deposition of the Person or Persons Most Knowledgeable to Testify on Behalf of John Hancock Life Insurance Co John Hancock Variable Life Insurance Co and Manulife Insurance Co fka Investors Partners Insurance Co in Re John Hancock Life Insurance Co et al vs Abbott Laboratories (Davis 1)		Davis_0001	Irrelevant	
[983]	D_HG	9/21/2000	Hartz Email re: Abbott (Davis 7)	JH002414 - JH002414	Davis_0007	Hearsay	
[984]	D_HK	06/15/2004	Desideri Letter re: Research Funding Agreement (Martinez_0001)	ABBT0000077 - ABBT0000078	Martinez_0001	Irrelevant	

John Hancock Life Insurance Company, et al. v Abbott Laboratories
Civil Action No. 05-11150-DPW
Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
[985]	D_IE	10/04/2000	Email re: Abbott John Hancock Research Funding Agreement (Lee 6)	JH003270 - JH003341	Lee_0006	Irrelevant/Hearsay	
[986]	D_IF		Lee Facsimile re: Draft Research Funding Agreement	JH008376 - JH008384	Lee_0017	Irrelevant	
[987]	D_LW	03/00/2001	Research Funding Agreement by and between Abbott Laboratories and John Hancock Life Insurance Co. et al. dated as of 03/00/2001 9 (Blewitt 24)	JH006002 - JH006009	Blewitt_0024	Irrelevant	
[988]	D_MB	06/03/2004	Campbell Email re: Hancock Audit (Campbell 10)	ABBT0126520 - ABBT0126520	Campbell_0010	Hearsay	
[989]	D_MC	06/04/2004	Wendrick Email re: Hancock Audit (Campbell 11)	ABBT0126590 - ABBT0126592	Campbell_0011	Hearsay	
[990]	D_MD	06/10/2004	Pavelske Email re Hancock Audit (Campbell 12)	ABBT0190551 - ABBT0190552	Campbell_0012	Hearsay	
[991]	D_ME	06/10/2004	Wendrick Email re: Hancock Audit Monday (Campbell 14)	ABBT0190544 - ABBT0190549	Campbell_0014	Hearsay	
[992]	D_MF	08/05/2004	Letter re: Research Funding Agreement between Abbott Laboratories Abbott and John Hancock Life Insurance Co. et al. dated 03/13/2001 (Campbell 21)	ABBT0000125 - ABBT0000127	Campbell_0021	Hearsay	
[993]	D_MG	02/19/2008	ALS Press Release entitled "Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin"			Hearsay	
994	D_MI	12/22/1998	M98-826 Phase II Osteoarthritis Pain Trial Protocol	ABBT0052076-ABBT0052167		No Objection	
995	D_MJ	01/05/1999	M98-833 Neuropathic Pain Protocol	ABBT0050285-ABBT0050361		No Objection	
996	D_MK	06/22/1999	M97-772 Molar Extraction Protocol	ABBT0052774-ABBT0052856		No Objection	

John Hancock Life Insurance Company, et al. v Abbott Laboratories

Civil Action No. 05-11150-DPW

Abbott Laboratories' Combined Trial Exhibit List

Admitted Ex. No.	Previous Ex. No.	Date	Description	Production Range	Deposition Exhibit No.	Hancock Objections	Date Admitted
[997]	D_ML	03/27/2000	Roth, Fleischmann Article titled "Around-the-Clock, Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain Placebo-Controlled Trial and Long-Term Evaluation"			Hearsay	
Judicial Notice 1		09/18/1998	International Conference on Harmonisation, 63 Fed. Reg. 49583 (Sept. 16, 2008)				
Judicial Notice 2		12/04/2000	Draft Guidance for Industry, 65 Fed. Reg. 75720 (Dec. 4, 2000)				

EXHIBIT E

John Hancock v. Abbott Laboratories**John Hancock's Objections to Abbott's Revised List of Proposed Trial Exhibits**

Key	
Code	Objection
AUTH	The proposed exhibit does not sufficiently indicate that it is what it purports to be, and is inadmissible under Fed. R. Evid. 901.
BATES	The proposed exhibit denotes a Bates range that appears to be in error. John Hancock requests that Abbott properly identify the proposed exhibit. Further, John Hancock reserves all objections to these documents.
HEAR	The proposed exhibit is Hearsay or Double Hearsay not within any exception, and is inadmissible under Fed. R. Evid. 802
IRREL	The proposed exhibit is irrelevant under Fed. R. Evid. 401, and thus inadmissible under Fed. R. Evid. 402.
MULTI	The proposed exhibit identifies more than one document. John Hancock requests that Abbott identify these documents with separate exhibit numbers. John Hancock reserves all objections to such documents.
No Objection	John Hancock does not object to the proposed exhibit.
SETTL	The proposed exhibit deals with settlement discussions and is thus inadmissible under Fed. R. Evid. 408.
PLs' "xx"	Abbott's proposed trial exhibit has been proposed as a trial exhibit by John Hancock, and has been objected to by Abbott. John Hancock urges Abbott to withdraw its objection to documents that Abbott now offers as trial exhibits in its own case.
Ex. "xx"	Abbott's proposed trial exhibit has been proposed as a trial exhibit by John Hancock, and has not been objected to by Abbott. The exhibit exists on the parties' list of "Agreed To" exhibits.
UNTIMELY	The proposed exhibit is being submitted by Abbott as part of the expert report of Avram Tucker. The exhibit was not previously included in that expert report, as required under the Scheduling Order in this case, and under Fed. R. Civ. P. 26(a)(2)(B). Hancock therefore objects to the exhibit as untimely.